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ABSTRACT
The ability to produce genetically superior livestock has established somatic cell
nuclear transfer (SCNT) as an invaluable tool in commercial livestock production.
Successful reprogramming of somatic cells towards pluripotency requires the epigenetic
marks characteristic of the differentiated cell type first be erased in order to inactivate
the somatic cell program and activate the embryonic program. Several small molecules
have been shown to improve both the kinetics and efficiency of reprogramming. These
chemical modifiers aid in overcoming the “roadblocks” encountered during the
reprogramming process by inducing the necessary epigenetic modifications needed to
silence the somatic cell genome and completely reactivate the embryonic stem cell
(ESC) genome. If small molecules are used to “prime” the somatic cells to be used as
donor cells in SCNT, the efficiency of nuclear reprogramming during SCNT may be
enhanced.
We first assessed the effect of pre-treatment with small molecules on the
expression of Oct-4, Nanog, and Sox-2 in bovine fetal fibroblast (BFF) cells. Chemical
treatment consisted of 3 small molecules: PD0325901, a mitogen activated protein
kinase/ERK kinase (MEK) inhibitor; CHIR99021, a glycogen synthase kinase-3 (GSK3)
inhibitor; and NuP0178, a G9a histone methyltransferase inhibitor. No significant
difference in transcript levels for Oct-4, Nanog, or Sox-2 was detected, indicating that
this combination of small molecule inhibitors does not have an effect on the expression
of Oct-4, Nanog, and Sox-2 in BFF cells.
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We next sought to assess the effects this combination of small molecule
inhibitors has on the epigenetic state of Oct-4, Nanog, and Sox-2 in BFF cells.
Chromatin Immunoprecipitation was used to quantify the enrichment of key histone
modifications on the promoter regions of Oct-4, Nanog, and Sox-3 in BFF cells treated
with and without PD0325901, CHIR99021, and NuP0178 over time. Time, treatment,
and a time*treatment interaction were found to have a significant effect on the histone
modifications analyzed. Determining how the expression of these factors alters the
epigenetic marks in the promoter regions of key pluripotency-associated genes will
allow for the development of defined conditions which best mimic the epigenetic
landscape of ESC, ultimately leading to engineering the ideal donor cell for successful
SCNT.
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CHAPTER I
INTRODUCTION
In 2006, Takahashi and Yamanaka reported the generation of a population of
cells similar to embryonic stem cells (ESC) by transfecting mouse tail fibroblast cells
with four transcription factor-encoding genes. These cells, termed induced pluripotent
stem cells (iPSC), are morphologically similar to pluripotent ESC and, most importantly,
demonstrate key characteristics of pluripotent ESC, including expressing stem cell
markers, forming teratomas containing cells of all three germ layers, and contributing to
multiple cell lineages (Takahashi and Yamanaka, 2006). This landmark discovery
paved the way for a rapidly progressing field of research.
The resetting of the somatic cell nucleus to an embryonic state involves several
complex mechanisms. The expression of Oct-4, Nanog, Sox-2 and other pluripotencyassociated genes is silenced through the differentiation-induced actions of DNA
methylation, histone deacetylation and histone methylation. These repressive
mechanisms that function to silence the embryonic program must be overcome during
reprogramming (Hochedlinger and Plath, 2009). These key developmental genes
contain bivalent domains consisting of both inhibitory H3K27 methylation marks and
activating H3K4 methylation marks. These bivalent domains are lost upon cellular
differentiation, indicating that they play an important role in maintaining pluripotency. In
addition, epigenetic silencing associated with H3K9 methylation also contributes to the
maintenance of pluripotency in ESC. H3K9me3 is associated with repressive
chromatin, and is maintained at low levels in ESC (Bernstein et al., 2006). These
marks are a key feature in the epigenetic signature of ESC.
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Studies have revealed that epigenetics play a crucial role in nuclear
reprogramming. Resistance to reprogramming is largely attributed to the phenomenon
of epigenetic memory that cells retain throughout numerous cell divisions. As cells
become more differentiated, they acquire epigenetic marks that make their nuclei
increasingly resistant to reprogramming (Pasque et al., 2011). However, modulations of
the epigenetic processes that accompany nuclear reprogramming may facilitate the
conversion to an epigenetic landscape that is more permissive to reprogramming.
Various tools have been employed to help cells overcome this reprogramming
roadblock, including the use of synthetic chemical epigenetic modulators known
collectively as “small molecules”. Several chemical compounds that control epigenetic
enzymes, such as HDAC, HMT, DNMT, and histone demethylase (HDM) have been
shown to improve reprogramming efficiency, or even replace the need to use certain
transcription factors (Zhang et al., 2012). This is especially promising for the clinical
application of iPSC as there are serious concerns regarding the safety of current
genetic approaches to nuclear reprogramming, as well as traditional culture systems
that are used to maintain iPSC. Small molecules provide an attractive approach to
addressing these challenges, as they offer a number of compelling advantages. First,
the biological effects of small molecules are typically rapid, reversible and dosedependent, allowing precise control over specific outcomes by fine-tuning their
concentrations and combinations. Second, the structural diversity that can be provided
by synthetic chemistry allows the functional optimization of small molecules. Third,
compared with genetic interventions, the relative ease of the handling and

2

administration of small molecules make them more practical for in vitro and in vivo
applications, and for further therapeutic development (Zhang et al., 2012).
Once established, cellular identity is remarkably stable. Chromatin modifications
are faithfully inherited from cell division to cell division, highlighting the major hurdles
iPSC must overcome in order to be fully reprogrammed to pluripotency. The use of
small molecule compounds that target chromatin modifications and/or specific signaling
pathways have proven to be effective at overcoming these reprogramming hurdles. In
the present study, we sought to assess the genetic and epigenetic effects pre-treatment
with a small molecule cocktail have on BFF cells.
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CHAPTER II
LITERATURE REVIEW
The History of Nuclear Reprogramming
In 2006, Takahashi and Yamanaka reported the generation of a population of
cells similar to ESC by transfecting mouse tail fibroblast cells with four transcription
factor-encoding genes. These cells, termed induced pluripotent stem cells (iPSC), are
believed to be immensely beneficial in the study and treatment of disease as the direct
reprogramming of somatic cells provides an opportunity to generate patient- or diseasespecific pluripotent stem cells (Nakagawa et al., 2008). The supposed potential of iPSC
lies in the fact that these cells are morphologically similar to pluripotent ESC and, most
importantly, demonstrate key characteristics of pluripotent ESC, including expressing
stem cell markers, forming teratomas containing cells of all three germ layers, and
contributing to multiple cell lineages (Takahashi and Yamanaka, 2006). This landmark
discovery has opened a new frontier in the field of regenerative medicine because, for
the first time, a realistic way of generating sufficient numbers of patient-specific
pluripotent stem cells exists (Amabile and Meissner, 2009). Furthermore, this method
of generating iPSC has provided researchers with a new and unique tool to study
mammalian development and the mechanisms underlying nuclear reprogramming.
The breakthrough discovery that lineage-restricted somatic cells can be
reprogrammed to a pluripotent state through the ectopic expression of defined
transcription factors represents the culmination of over 50 years of research. The
history of nuclear reprogramming begins in 1952 with Briggs and King. The longstanding question of whether the process of development and cell differentiation
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irreversibly alters the genome prompted Briggs and King (1952) to develop a system to
directly test the genetic equivalence of somatic cell nuclei and embryonic cell nuclei. In
this first published nuclear transfer study, Briggs and King (1952) reported generating
cloned frogs by transferring nuclei isolated from late-stage embryos into enucleated
oocytes. This work, together with seminal studies by Gurdon (1962; Gurdon et al.,
1975), provided the first conclusive evidence that genes of somatic cells are not
irreversibly changed during differentiation. Furthermore, these studies demonstrated
the ability of the oocyte cytoplasm to facilitate the de-differentiation of the somatic cell
nuclei in order to reset the developmental program (Briggs and King, 1952; Gurdon,
1962; Gurdon et al., 1975).
Despite the early success of nuclear transplantation in frogs, it was not until 1997
that the first mammal was successfully cloned using somatic cell nuclear transfer
(SCNT). The birth of “Dolly”, a cloned sheep produced by fusing a mammary cell that
had been induced to enter a quiescent state with an enucleated oocyte (Wilmut et al.,
1997), marks one of the most celebrated events in the history of biological research.
Heralded by Science magazine as “the breakthrough of 1997”, “Dolly” decisively proved
that even a fully differentiated mammalian somatic cell can be reverted to an embryonic
state when transferred into an enucleated oocyte (Wilmut et al., 1997). In spite of a 45
year gap between the first nuclear transfer experiment by Briggs and King (1952) and
the birth of “Dolly”, many key discoveries in the field of nuclear reprogramming were
made during this 45 year period, including the development of different techniques that
allowed researchers to derive, culture and study pluripotent cell lines. Scientists’
earliest insight into the nature of pluripotent cells came from studying embryonal
5

carcinoma cells (ECC). Derived from germ cell tumors known as teratocarcinomas,
researchers discovered that ECC could be clonally expanded in culture while remaining
pluripotent (Finch and Ephrussi, 1967). The establishment of these immortal pluripotent
cell lines marks a key event in the history of nuclear reprogramming because it provided
scientists with a tool to explore the regulatory mechanisms underlying pluripotency.
Among these scientists were Miller and Ruddle, who showed that the hybrid cells
resulting from the fusion of murine teratocarcinoma cells and thymus cells adopted the
biochemical and development properties of their ECC parent (Miller and Ruddle, 1976).
The dominance of the pluripotent state over that of the somatic cell suggested that gene
expression is not only regulated by cis-acting DNA elements but also by trans-acting
factors present in ECC that confer pluripotency in somatic cells upon fusion (Stadtfeld
and Hochedlinger, 2010). Short-lived, non-dividing, multinucleate fusion products of two
distinct cell types, known as heterokaryons provided the first definitive evidence that
previously silent genes typical of diverse differentiated mammalian cells could be
activated in other differentiated cell types (Blau et al., 1983). Because a proliferating
population of hybrid cells often results in nuclear fusion, loss and rearrangement of
chromosomes, gene activation as a result of nuclear reprogramming cannot accurately
be assessed. Heterokaryons, on the other hand, do not divide; therefore, the nuclei of
the two cells remain distinct and intact (Yamanaka and Blau, 2010). In the first
heterokaryon study, human amniotic cells and murine muscle cells were fused together
to form heterokaryons that expressed several muscle proteins, indicating that muscle
genes had been activated in non-muscle cells (Blau et al., 1983). The belief that
previously silent genes could be activated in muscle-cell-containing heterokaryons was
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corroborated by other groups soon after (Wright, 1984), and it quickly became apparent
that this was true for other cell types as well.
The results of these heterokaryon experiments lead researchers to the make the
same conclusion about mammalian somatic cells as Briggs and King (1952) and
Gurdon (1962; Gurdon et al., 1975) did about amphibian somatic cells years before: the
differentiated state of somatic cells is not fixed and irreversible. Instead, these
experiments illustrated that the generally stable state of differentiated somatic cells can
be altered in response to changes in the cells’ environment, lending support to the
theory of cellular plasticity. Researchers hypothesized that the differentiated state of
somatic cells is dictated by the balance of regulators and requires continuous
regulation. Alterations in the cells’ environment induce perturbations in the
stoichiometry of these regulators, allowing the fate of somatic cells to change (Blau et
al., 1983). These observations prompted researchers to further investigate the
regulators responsible for maintaining the differentiated state of somatic cells and how
changes in the levels of these regulators in the cell can alter cell fate. In 1987,
Schneuwly et al. demonstrated that the overexpression of a D. melanogaster homeotic
gene, Antennapedia, under the control of a heat-shock gene promoter led to the
formation of an additional set of legs instead of an antenna. Around the same time, the
first mammalian master regulatory transcription factor, MYOD, was identified. Davis et
al. (1987)reported the formation of myofibers in murine fibroblast cell lines transduced
with retroviral vectors expressing the skeletal muscle transcription factor MYOD,
demonstrating that overexpression of this single transcription factor is sufficient to
convert fibroblast to myoblast. These studies demonstrated that lineage-associated
7

transcription factors-which help to establish and maintain cellular identity during
development by driving the expression of cell type-specific genes while suppressing
lineage-inappropriate genes-can change cell fate when ectopically expressed in certain
heterologous cells (Stadtfeld and Hochedlinger, 2010). Importantly, these studies
prompted a more systematic search for transcription factors that could induce the
conversion of differentiated cells to a pluripotent state. Almost 20 years later, these
factors were identified (Takahashi and Yamanaka, 2006).

Nuclear Reprogramming Strategies
Each of the aforementioned experiments represents a major milestone in the
history of nuclear reprogramming. These key discoveries have impacted the field of
nuclear reprogramming by providing scientists’ not only with a better understanding of
the mechanisms underlying the process of nuclear reprogramming but also with the
conceptual framework needed for the development of current reprogramming
techniques. Currently, there are four methods of reprogramming differentiated somatic
cells to a pluripotent state: SCNT (Wilmut et al., 1997), fusion with ESC (Cowan et al.,
2005), exposure to ESC extracts (Bru et al., 2008), introduction of defined factors
(Takahashi and Yamanaka, 2006).
Somatic Cell Nuclear Transfer
In 1997, Wilmut and colleagues introduced the world to “Dolly”, the first
successfully cloned mammal from an adult cell. By fusing a mammary epithelial cell
from a Finn Dorset ewe with an enucleated donor oocyte, Wilmut et al (1997)
unknowingly created “the world’s most famous sheep”. Since the birth of “Dolly”, a wide
8

range of species have been successfully cloned using SCNT, including domesticated
animals such as the cow (Kato et al., 1998) and dog (Lee et al., 2005), as well as wild
animals like the African wildcat (Gomez et al., 2004) and wolf (Kim et al., 2007).
Wilmut and colleagues succeeded at what had been deemed for many years as
“biologically impossible”. The birth of “Dolly”, however, provided clearly convincing
evidence that the nucleus of even fully differentiated mammalian cells can be
reprogrammed to an embryonic state when transferred into enucleated oocytes (Wilmut
et al., 1997). Wilmut and colleagues succeeded at what others had been attempting for
years by implementing cell cycle synchronization into their strategy. They theorized that
inducing the donor cells to exit the cell cycle by serum deprivation would change the
chromatin structure in such a way that was conducive to nuclear reprogramming.
Under normal conditions in vivo, high levels of Maturation Promoting Factor (MPF)
found in the cytoplasm of metaphase II (MII) oocytes induce nuclear envelope
breakdown and chromosome condensation to facilitate entry into the M phase of the cell
cycle. The activity of MPF can have beneficial or harmful effects upon the
reconstructed embryo depending on the cell cycle stage of the donor cell (Campbell et
al., 1993; Fulka et al., 1998). High levels of MPF in the MII oocyte cause nuclear
envelope breakdown and chromosome condensation in the transferred nucleus,
irrespective of cell cycle stage of the donor cell. If the nucleus is in S or G2 phase, then
the potential for reduplication of the genome directed by the recipient cytoplasm will
result in aberrant development (Hanocq-Quertier et al., 1976; Sunkara et al., 1979;
Campbell et al., 1996; Kikyo and Wolffe, 2000). If DNA synthesis is not yet complete,
initiation of premature nuclear envelope breakdown and chromosome condensation will
9

lead to chromosome loss and aneuploidy (Kikyo and Wolffe, 2000). To facilitate proper
nuclear remodeling by MPF, the donor nuclei should be in G1 phase or G0 phase, in
which the cells remain metabolically active but have exited the cell cycle. Donor nuclei
in G1 or G0 phase transferred to recipient oocytes containing high levels of MPF will
condense normally and maintain correct ploidy of subsequent embryos at the end of the
first cycle (Campbell et al., 1993; Macháty et al., 2002). The usefulness of quiescent
cells has been attributed to their reduced transcriptional activity and chromatin
modifications that are associated with cells in G0, which may enhance their epigenetic
plasticity (Armstrong et al., 2006).
A number of critical processes must occur and a temporal pattern of events will
have to be obeyed in order to achieve reprogramming of the somatic cell nucleus by
SCNT. These processes include transcriptional silencing of the donor nucleus, erasure
of differentiated cellular memory, appropriate activation of the reconstructed “one-cell
embryo”, and appropriate embryonic gene expression at all later stages of development
(Santos and Dean, 2004). This cascade of reprogramming of events is initiated by the
exchange of proteins that occurs when a somatic cell donor nucleus is transplanted into
an enucleated oocyte. The first indication of nuclear reprogramming is the breakdown
of the somatic cell nuclear envelope. As discussed above, nuclear envelope breakdown
is associated with high MPF levels. Soon thereafter, the somatic cell chromosomes
begin to condense. All of the factors necessary for reprogramming the somatic cell
nuclei back to a totipotent state are present in the MII oocyte cytoplasm.

Researchers

have been exploring these reprogramming factors since Wilmut et al. (1997) first
reported the successful production of a cloned sheep, and although more than a decade
10

has passed, they remain largely unknown. Some proteins have been identified,
including nucleoplasmin and N1/N2. Both of these molecular chaperones can mediate
the transfer of core histones to DNA and the assembly of nucleosomes. Nucleoplasmin
plays a role in the exchange of the somatic linker histone variants (H1, H1˚) for oocytespecific histone variant B4 and the chromatin structural protein HMG1 (Dimitrov and
Wolffe, 1996).
Since the birth of Dolly, viable NT-derived offspring have been produced in many
species ranging from domesticated animals such as dogs and goats, to wild animals
such as African wildcats and wolves (Thuan et al., 2010). Nevertheless, the overall
efficiency of SCNT is between 0-3% (number of live offspring as a percentage of the
number of nuclear transfer embryos) (Paterson et al., 2003). The majority of cloned
embryos die in utero, and those embryos that do develop to term often exhibit a variety
of developmental abnormalities. Placental abnormalities are a common feature among
NT embryos and account for the high incidence pregnancy loss associated with NT
embryos. It is thought that defects in placental function are also responsible for many of
the developmental abnormalities in cloned fetuses, including Large Offspring Syndrome
(Yang et al., 2007).
While a great deal of the attention “Dolly” garnered stemmed from intense public
debate over ethical concerns regarding cloning, many in the agricultural, scientific and
medical community were excited over the potential applications of SCNT. SCNT may be
used to produce multiple copies of a genetically superior farm animal with proven
performance. Additionally, SCNT may be used to preserve endangered species. Given
that somatic cells are easily obtained from adult animals, cultured in the laboratory and
11

then genetically modified, cloning procedures are ideal for introducing specific genetic
modifications in farm animals. Transgenic animal production provides numerous
opportunities not only for agriculture, but for biomedicine as well, as these animals can
be used for the production of pharmaceutical proteins or xenotransplantation (Whyte
and Prather, 2011). In recent years, however, the potential capabilities of SCNT have
been overshadowed by ethical concerns as well as the inefficient nature of the
procedure, leading researchers to explore alternative reprogramming methods for the
generation of ESC-like cells.
Fusion with ESC
Cell fusion studies date back to the 1960’s. These pioneering experiments
provided novel evidence that gene expression is regulated not only by cis-acting DNA
elements but also by trans-acting repressors (Harris et al., 1969; Miller and Ruddle,
1976; Weiss et al., 1977). Approximately a decade later, cell fusion studies offered the
first definitive evidence that the differentiated state of mammalian somatic cells is not
fixed and irreversible but, instead, is dictated by the balance of regulators and requires
continuous regulation (Blau et al., 1983; Blau et al., 1985; Blau and Baltimore, 1991).
Such studies could not be taken further until recent molecular technologies were
developed, at which point cell fusion experiments showed that the pluripotent state can
dominate over the differentiated state under certain conditions, resulting in the activation
of previously silenced genes (Yamanaka and Blau, 2010). Tada and colleagues (1997)
reported the first successful reprogramming of somatic cells in proliferative hybrids after
they fused female EGC with thymocytes from an adult male. They continued their cell
fusion experiments, and in 2001 reported that thymocytes were reprogrammed to a
12

pluripotent state after being fused with mouse ESC (mESC). 48 hours after fusion with
mESC, Oct-4 was reactivated in hybrid cells, indicating pluripotency had been
reestablished.

This was also testified by the hybrids’ contribution to all three germ

layers as well as the epigenetic status as assessed by DNA methylation patterns of
imprinted and non-imprinted genes (Tada et al., 2001). Rathjen and colleagues (2002)
produced similar results when they fused mouse ESC-derived neuroectoderm with
undifferentiated mouse ESC, resulting in hybrid cells that expressed pluripotencyassociated genes at levels comparable to those in ESC.

To test if human ESC were

capable of nuclear reprogramming like their murine counterpart, Cowan et al (2005)
fused human ESC with human fibroblast cells. Following fusion, hybrid cells containing
both ESC and fibroblast cell chromosomes in a single nucleus were formed; however,
the hybrid cells exhibited characteristics consistent with the ESC, indicating that the
phenotype of human ESC is dominant and that they are also capable of reprogramming
human somatic cells (Cowan et al., 2005). Furthermore, DNA analysis showed that the
promoter region of Oct-4 in the hybrid cells was demethylated and indistinguishable
from that found in human ESC, proving that the epigenetic information controlling the
transcription of pluripotency genes was reprogrammed (Cowan et al., 2005).
Unlike the ooplasm of an enucleated oocyte in SCNT, nuclear reprogramming of
a somatic cell to a less differentiated state through cell fusion is governed by ESC
nuclei, which reactivates pluripotency-associated genes and silences the gene
expression of the somatic cell. When the nucleus and the cytoplasm of mESC were
fused with neurosphere cells, only karyoplasts, not cytoplast, could reactivate Oct-4 in
the somatic genome (Do and Schöler, 2004). This is consistent with cloning
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experiments in amphibians and mice, which indicate that successful reprogramming
depends on direct injection of nuclei into the MII oocyte, where nuclear factors are
available in the cytoplasm (Hochedlinger and Jaenisch, 2006).
Cell fusion is an attractive approach to studying pluripotency and the regulatory
mechanisms involved in nuclear reprogramming. Although it is well established that
somatic cells can be reprogrammed to a pluripotent state through fusion with various
pluripotent cell types, cell fusion for the generation of pluripotent cells for clinical or
therapeutic application is not best. Hybrid cells contain an abnormal ploidy as well as
nonautologous genes from the pluripotent parent, which could result in immune
rejection (Pralong et al., 2006). Removal of the pluripotent genome must be achieved
before the hybrid cells can be used clinically.
Exposure to ESC Extracts
Cell fusion experiments involving the fusion of pluripotent cell types with various
somatic cell types provided critical insight of the molecular regulators of nuclear
reprogramming. The work of Tada and colleagues (1997, 2001) as well as Cowen and
colleagues (2005) showed that pluripotent cells can trigger epigenetic reprogramming to
a less differentiated state in a variety of somatic cell types after cellular fusion, proving
that pluripotent cell types harbor dominant reprogramming activities. It was experiments
like these that provided the inspiration for the development of a cell-free means to
reprogramming the nuclei of somatic cells to a pluripotent state. One such way of doing
this is through exposure to ESC extracts. Ha°kelien et al (2002) had previously
demonstrated the reprogramming abilities of cellular extracts using human 293T
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fibroblast cells and human T cells. Ha°kelien et al (2002) derived nuclear and
cytoplasmic extracts from human peripheral blood T cells by lysing the cells using a
sonicator. For the 293T cells to take up the T cell extracts, their cellular membrane was
permeabilized using Streptolysin O (SLO), which binds to cholesterol in the cell
membrane and forms holes in the plasma membrane of the cell. The T cell extracts and
the permeabilized 293T cells were incubated together for approximately 50 min and
then the plasma membrane was resealed using a CaCl2-containing cocktail (Ha°kelien
et al., 2002). Plasma membrane resealing following SLO exposure is dependent upon
Ca+2, as the Ca+2 influx triggers a rapid repair process to the permeabilized plasma
membrane (Walev et al., 2001).
Using the same method of extract derivation and membrane permeabilization as
described by Ha°kelien et al (2002), Taranger and colleagues (2005) demonstrated that
extracts from both undifferentiated ECC and ESC can induce somatic cells to
dedifferentiate and, in turn, acquire pluripotent characteristics. 293T cells exposed to
human teratocarcinoma NCCIT cell extracts and mESC extracts formed defined
colonies that were maintained for an extended period of time in culture. Gene
expression profiling revealed a dynamic up-regulation of genes associated with
undifferentiated cell types, parallel with down-regulation of 293T cell genes and other
genes associated with differentiated cell types. Pluripotency-associated genes Oct-4,
Nanog, and Sox-2 were among the genes up-regulated in 293T cells exposed to
extracts of undifferentiated cell types. Bisulfite sequencing revealed that the Oct-4
promoter was demethylated in extract-treated 293T cells, suggesting that NCCIT and
mESC extracts are capable of eliciting Oct-4 demethylation in somatic cells.
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Additionally, extract-treated 293T cells demonstrated multilineage differentiation
capabilities by giving rise to cell types of the three germ layers (Taranger et al., 2005).
In an effort to better understand the molecular processes underlying nuclear
reprogramming, researchers built upon this study and were able to provide evidence of
reprogramming of DNA methylation and histone modifications on the Nanog promoter
and throughout the Oct-4 regulatory region in human epithelial cells (Freberg et al.,
2007). In order to identify those cells that had been stably reprogrammed to express
pluripotency-associated genes, the treated cells in all of the aforementioned studies had
to be grown in culture for several weeks, which makes it difficult to ascertain
reprogramming efficacy as well as complicating further biochemical analysis procedures
(Bru et al., 2008). In 2008, however, Bru et al. reported the detection of key
pluripotency-associated genes in ESC-extract treated cells within a few hours of
exposure, proving the first stages of reprogramming do not require a long incubation
period. Interestingly, the expression of these genes increased in the 48 hours following
exposure to extracts, indicating that long-term reprogramming of gene expression had
been induced (Bru et al., 2008). While further studies to validate extract-based nuclear
reprogramming are needed, it has proven to be an effective means to nuclear
reprogramming, which may be a more appealing option of generating iPSC than by
either SCNT or cell fusion.
Nuclear reprogramming techniques are believed to be immensely beneficial in
the study and treatment of disease as the direct reprogramming of somatic cells
provides an opportunity to generate patient- or disease-specific pluripotent stem cells
(Nakagawa et al., 2008). While all four experimental techniques have demonstrated the
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ability to successfully reprogram gene expression and promote pluripotency in
terminally differentiated cells (Thomson et al., 1998; Cowan et al., 2005; Takahashi and
Yamanaka, 2006; Bru et al., 2008), not all of the methods are suitable for generating
iPSC for clinical use. Aside from the obvious ethical issues regarding nuclear
reprogramming by SCNT and fusion with ESC, major technical obstacles impede their
clinical applications. The inefficient nature of SCNT, coupled with the fact that it is a
technically challenging procedure, make it unlikely that SCNT could be performed on a
large scale to derive pluripotent cell lines routinely for every patient (Amabile and
Meissner, 2009). Although nuclear reprogramming by fusion with ESC circumvents
these hindrances, abnormal ploidy and the presence of nonautologous genes from the
pluripotent parent cells prevent the therapeutic use of pluripotent hybrid cells (Pralong et
al., 2006). For this approach to be viable, a practical means of removing the nucleus of
the ESC from the hybrid cell must be developed in order to generate diploid customized
cells for transplantation therapy. It will be difficult, if not impossible, to selectively
eliminate the entire set of ESC chromosomes from the hybrid cells if future research
determines DNA replication is required for reprogramming (Hochedlinger and Jaenisch,
2006).
Extract-based nuclear reprogramming of differentiated somatic cells is an
attractive means of generating large quantities of pluripotent cells. Two advantages of
extract-mediated nuclear reprogramming are the absence of introduction of ESC
chromosomes into the cell to be reprogrammed, and the possibility of identifying
reprogramming factors and mechanisms of reprogramming (Collas, 2007). Extractderived factors are presumably not permanently active in target cells but turn over at
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kinetics corresponding to their half-lives. By circumventing the use of whole cells, the
difficulties associated with removal of extra chromosomes are eliminated (Dittmar et al.,
2009). Furthermore, the use of permeabilized cells allows the reprogramming factors to
access the interior directly, which may not only be more effective but has the advantage
of being useful without having a great deal of prior knowledge of regulatory mechanisms
controlling cell function. From a commercial standpoint, extract-based reprogramming
is far more practical than SCNT. Cells are the source of reprogramming material,
which, unlike oocytes, can be grown in large numbers, and, if necessary, can be
transformed to produce a consistent supply of reprogramming material. Importantly, in
vitro reprogramming may be applied to many cell types and thus has potential to treat
many diseases (Collas, 2007).
Defined Factors
One of the most significant breakthroughs in stem cell research to occur in recent
years is the production of iPSC by defined factors. Indeed, it is arguably the most
celebrated scientific advancement since the birth of “Dolly”. Like the previously
mentioned methods of generating iPSC, the ectopic expression of defined transcription
factors can also generate genetically-tailored stem cells for therapeutic use by
reprogramming the nucleus of a differentiated cell to function like that of an ESC. In
contrast to the production of iPSC by SCNT, fusion with ESC or exposure to ESC
extracts, the defined factors methodology is far less controversial because it does not
make use of ESC or oocytes. Instead, this technique relies upon the actions of four
transcription factors to elicit pluripotent cells from otherwise developmentally-restricted
cells. Considering the transcription factors known to function in the maintenance of
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pluripotency in ESC as well as those specifically expressed in ESC, Takahashi and
Yamanaka (2006) selected 24 genes as contenders for factors capable of inducing
pluripotency in somatic cells. To determine which genes are critical for reprogramming
a somatic cell to an ESC-like state, Takahashi and Yamanaka (2006) developed an
assay system in which a gene’s ability to induce pluripotency was determined by its
ability to trigger the formation of G418-resistant colonies following its induction to mouse
embryonic fibroblast cultures by retroviral transduction. Of these 24 genes, Oct-4, Sox2, c-Myc and Klf-4 were identified as the essential factors for generating iPSC directly
from fibroblast culture (Takahashi and Yamanaka, 2006). The resultant iPSC exhibited
morphological features and proliferative properties consistent with ESC, and also
expressed ESC marker genes. Furthermore, subcutaneous injection of the iPSC in
nude mice elicited the formation of teratomas that contained tissues from all three germ
layers, indicative of the pluripotent state of the iPSC (Takahashi and Yamanaka, 2006).
The crucial roles Oct-4 and Sox-2 play in maintaining ESC identity are well established;
therefore, it was not surprising to discover they also serve in the direct production iPSC
in culture. However, it was surprising to find that Nanog, whose expression is essential
to the pluripotent-state of ESC, was dispensable to this process, whereas c-Myc and
Klf-4 were imperative (Takahashi and Yamanaka, 2006). c-Myc and Klf-4 are proposed
to indirectly enhance Oct-4, Sox-2 and Nanog function, respectively, in the iPSC. It is
believed that c-Myc may induce global histone acetylation in the mammalian genome
(Fernandez et al., 2003), which, in turn, potentiates Oct-4 and Sox-2 target binding. Klf4, on the other hand, may contribute to Nanog activation by repressing p53, which is
known to suppress Nanog expression in ESC during differentiation (Lin et al., 2005).
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Indeed, the exact mechanisms these factors employ to induce pluripotency in somatic
cells is undetermined, however, their ability to do so is universal. Although human ESC
differ from murine ESC in many aspects, Takahashi et al. (2007) reported the
generation of iPSC from adult human fibroblast cultures using the same defined factors
less than a year after their initial study. The functional uniformity of Oct-4, Sox-2, c-Myc
and Klf-4 across species suggests that these four factors are fundamentals of a
common pluripotency-governing system. Furthermore, the similarities in morphology,
proliferation, surface antigens, gene expression, epigenetic status of pluripotent cellspecific genes, telomerase activity, and pluripotent differentiation ability noted between
human iPSC and true human ESC (Nakagawa et al., 2008) are similar to those
observations between murine iPSC and murine ESC (Takahashi and Yamanaka, 2006).

Epigenetic Reprogramming
In all of the aforementioned reprogramming strategies, differentiated somatic
cells are reverted to an ESC-like state as a result of changes in the epigenome.
Although epigenetic modifications are heritable, all four reprogramming methodologies
have demonstrated that these modifications can be experimentally reversed.
Epigenetic changes are heritable modifications to DNA or chromatin that allow
differentiated cells to perpetuate the molecular memory needed to retain their identity
(Tada et al., 1997; Jones and Takai, 2001). The principle function of epigenetic
modifications is to regulate the repression of genes not required in specific cell types at
specific stages of development without changing DNA sequence (Wolffe and Matzke,
1999).
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Successful reprogramming of somatic cells towards pluripotency requires the
epigenetic marks characteristic of the differentiated cell type first be erased in order to
inactivate the somatic cell program and activate the embryonic program. Recent
studies reporting the activation of the embryonic marker SSEA 1 following the
downregulation of somatic markers, such as Thy 1 and collagens, provide evidence in
support of the notion that silencing the somatic cell program is an important initial step
in re-establishing pluripotency (Brambrink et al., 2008; Stadtfeld et al., 2008). The
activation of SSEA 1 in reprogrammed fibroblast cells is an especially important
intermediate stage of transcription factor-induced reprogramming because it promotes
the gradual reactivation of other markers associated with pluripotency, including Oct-4,
Nanog, Sox-2, telomerase and the silent X chromosome in female fibroblasts
(Brambrink et al., 2008; Stadtfeld et al., 2008).
The expression of Oct-4, Nanog, Sox-2 and other pluripotency-associated genes
is silenced through the differentiation-induced actions of DNA methylation, histone
deacetylation and histone methylation. These repressive mechanisms that function to
silence the embryonic program must be overcome during reprogramming (Hochedlinger
and Plath, 2009). Regardless of the methodology employed, nuclear reprogramming is
associated with a global reversal of DNA methylation. Both active and passive
mechanisms of DNA demethylation have been proposed to occur in reprogramming, but
the precise nature of the mechanisms underlying nuclear reprogramming remains
largely unknown. It is possible that reprogramming by defined factors facilitates the
direct binding of these factors to promoter or enhancer regions of target sites, which
interfere with the methylation of newly synthesized DNA during DNA replication.
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Similarly, passive demethylation could also occur as a result of stochastic impairments
to specific factors known to contribute to the stable inheritance of methylation patterns,
thus inhibiting Dnmt-1 function indirectly (Hochedlinger and Plath, 2009).
Inefficient reprogramming in SCNT embryos has been linked to flaws in the
demethylation process. This may in part be due to the fact that the somatic nuclei
contain the somatic form of Dnmt-1, which, unlike the oocyte form, is capable of
maintaining methylation levels (Reik et al., 2001).

Alternatively, DNA methylation

could be actively removed by the recruitment of a demethylating enzyme, although the
presence of demethylation enzymes in mammalians is still under debate (Hochedlinger
and Plath, 2009).

Small Molecules
The notion that the aforementioned repressive mechanisms that function to
silence the embryonic program actions must be overcome in order for successful
nuclear reprogramming to occur has prompted the use of various chemical inhibitors
involved in DNA methylation, histone deacetylation and histone methylation. Such
chemical inhibitors aid in overcoming the “roadblocks” encountered during the
reprogramming process by inducing the necessary epigenetic modifications needed to
silence the somatic cell genome and completely reactivate the ESC genome. Several
small molecules, affecting specific signaling pathways and/or chromatin modifications,
have been shown to improve both the kinetics and efficiency of reprogramming
(summarized in Table 2.1)(Zhang et al., 2012). In addition, pre-treatment of cells with
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Table 2.1. Known compounds that modulate stem cell fate and reprogramming
Compound
name

Identity

Function

References

Epigenetic-related compounds
Promotes MEF reprogramming
Valproic acid
(VPA)

HDAC inhibitor

efficiency, and enables Oct4- and

(Huangfu et al., 2008a;

Sox2-mediated reprogramming of

Huangfu et al., 2008b)

human fibroblasts;
VPA

HDAC inhibitor

Suberoylanilide
hydroxamc acid

HDAC inhibitor

facilitates proteins mediated
reprogramming of MEFs
Promotes MEF reprogramming
efficiency

(SAHA)
Trichostatin A
(TSA)
Sodium butyrate
(NaB)

HDAC inhibitor

HDAC inhibitor

Promotes MEF reprogramming
efficiency
Enhances reprogramming efficiency
of human adult or fetal fibroblasts;

(Zhou et al., 2009)

(Huangfu et al., 2008a)

(Huangfu et al., 2008a)

(Mali et al., 2010)

facilitates Oct4-only mediated
NaB

HDAC inhibitor

reprogramming when combined with

(Zhu et al., 2010)

A-83-01/PD0325901/PS48
Enables NPC reprogramming
BIX-01294

G9a HMT

mediated by Oct4 and Klf4, or

inhibitor

substitutes for Oct4 in NPC

(Shi et al., 2008b)

reprogramming;
BIX-01294

G9a HMT

promotes MEF reprogramming

inhibitor

mediated by Oct4 and Klf4

(Shi et al., 2008a)

Promotes MEF reprogramming
RG108

DNMT inhibitor

mediated by Oct4 when combined

(Shi et al., 2008a)

with BIX-01294
Enables reprogramming of human
Parnate

LSD1 inhibitor

keratinocytes mediated by Oct4 and

(Li et al., 2009b)

Klf4;
Parnate

LSD1 inhibitor

facilitates the conversion of mEpiSCs
to naïve pluripotent state

Table Cont’d
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(Zhou et al., 2010)

Compound
name
PD0325901

PD0325901

PD0325901

Identity

MEK inhibitor

MEK inhibitor

MEK inhibitor

Function

References

Blocks differentiation pathway of

(Ying et al., 2008;

ESCs and supports self-renewal;

Tsutsui et al. 2011)

supports ESC derivation from
refractory strains or species;

(Nichols et al.,
2009;Buehr et al.,
2008; Li et al., 2008)

facilitates conversion of mEpiSCs and

(Hanna et al., 2010;

hESCs to naïve pluripotent state;

Zhou et al., 2010)

facilitates generation and
PD0325901

MEK inhibitor

maintenance of mESC-like rat or

(Li et al., 2009a)

human iPSCs;
facilitates rapid and efficient
PD0325901

MEK inhibitor

generation of fully reprogrammed

(Lin et al., 2009)

hiPSCs;
enables Oct4-mediated
PD0325901

MEK inhibitor

reprogramming when combined with

(Zhu et al., 2010)

A-83-01/NaB/PS48
Supports ESCs self-renewal;
CHIR99021

GSK3 inhibitor

facilitates ESCs derivation from
refractory stains or species
captures and maintains lineage-

CHIR99021

GSK3 inhibitor

specific stem cells, like pNSCs;
facilitates the conversion of mEpiSCs
and hESCs to naïve pluripotent state;

CHIR99021

GSK3 inhibitor

(Ying et al., 2008;
Tsutsui et al. 2011)

(Nichols et al., 2009;
Buehr et al., 2008; Li et
al., 2008)

enables Oct4- and Klf4-mediated

(Li et al., 2009a; Hanna

reprogramming of MEFs or human

et al., 2010; Zhou et al.,

primary keratinocytes with Parnate;

2010; Li et al., 2009b)

facilitates generation and
CHIR99021

GSK3 inhibitor

maintenance of mESC-like rat or

(Li et al., 2009a)

human iPSCs;
facilitates the neural conversion of
CHIR99021

GSK3 inhibitor

human fibroblasts mediated by Ascl1
and Ngn2

Table Cont’d
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(Ladewig et al., 2012)

Compound
name

Identity

6bromoindirubin-

GSK3 inhibitor

3′-oxime (BIO)
Kenpaullone

PD173074

PD173074

SU5402

A-83-01

A-83-01

A-83-01

SB431542

SB431542

SB431542

E-616452

Compound E

GSK3 and CDK
inhibitor
FGF receptor
inhibitor

Function

References

Promotes self-renewal of ESCs and

(Sato et al., 2004;

Isl+ cardiovascular progenitors

Qyang et al., 2007)

Replaces Klf4 in MEF reprogramming

(Lyssiotis et al., 2009)

Supports mESC self-renewal;

(Buehr et al., 2008)

FGF receptor

facilitates the conversion of mEpiSCs

inhibitor

to naïve pluripotent state

FGF receptor
inhibitor

Supports mESC self-renewal

ALK4, ALK5,

Facilitates the conversion of mEpiSCs

ALK7 inhibitor

to naïve pluripotent state;

ALK4, ALK5,
ALK7 inhibitor

ALK4, ALK5,
ALK7 inhibitor

maintenance of mESC-like human

reprogramming when combined with

generation of fully reprogrammed

(Lin et al., 2009)

human iPSCs;
Facilitates the neural conversion of
human fibroblasts mediated by Ascl1

(Ladewig et al., 2012)

and Ngn2
Replaces Sox2 in MEF

ALK7 inhibitor

reprogramming.

inhibitor

(Li et al., 2011)

facilitates rapid and efficient

ALK4, ALK5 and

γ-secretase

(Zhu et al., 2010)

PD0325901/NaB/PS48

combined with CHIR99021;

ALK7 inhibitor

(Li et al., 2009a)

enables Oct4-mediated

ALK7 inhibitor

ALK4, ALK5,

(Zhou et al., 2010)

iPSCs;

Captures and maintains pNSCs when

ALK7 inhibitor

(Buehr et al., 2008)

enables generation and long-term

ALK4, ALK5,

ALK4, ALK5,

(Zhou et al., 2010)

Accelerates the generation of pNSCs

Table Cont’d
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(Ichida et al., 2009;
Maherali and
Hochedlinger, 2009)
(Li et al., 2011)

Compound
name
JAK Inhibitor I

Pluripotin (SC1)

Y-27632

Thiazovivin
(Tzv)
Thiazovivin
(Tzv)

StemRegenin1

Identity

JAK inhibitor
RasGAP and
ERK inhibitor

ROCK inhibitor

ROCK inhibitor

Function

References

Inhibits the generation of iPSCs in

(Efe et al., 2011; Kim et

iPSC-TF-based transdifferentiaion

al., 2011a)

Maintains mESC self-renewal

(Chen et al., 2006)

Improves survival of hESCs upon
dissociation
Improves survival of hESCs upon
dissociation;

(Chen et al., 2010;
Ohgushi et al., 2010;
Xu et al., 2010)
(Xu et al., 2010)

facilitates rapid and efficient
ROCK inhibitor

generation of fully reprogrammed

(Lin et al., 2009)

hiPSCs
AhR antagonist

Enables ex vivo expansion of CD34+
HSCs ex vivo

(Boitano et al., 2010)

Enables OCT4-mediated
PS48

PDK1 activator

reprogramming with A-83-01, NaB

(Zhu et al., 2010)

and PD0325901

BayK8644

L-type Ca2+
channel agonist

Promotes MEF reprogramming
mediated by Oct4 and Klf4 when

(Shi et al., 2008a)

combined with BIX-01294
Induces Klf4 and Klf2 expression to

Forskolin

PKA agonist

facilitate hESCs conversion into a
naïve pluripotent state
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(Hanna et al., 2010)

chemical inhibitors can remodel the epigenetic landscape of the somatic cell type to be
more like that of ESC by removing the repressive epigenetic marks and relaxing
chromatin structure to allow the reprogramming factors easier access to target genes.
DNA Methyltransferase Inhibitors
Methylated CpG sites in gene promoter regions are easily recognized by specific
methyl CpG binding proteins, which act as adapters between methylated DNA and
chromatin modifying factors. These proteins can recruit co-repressors, such as histone
deacetylases (HDAC), methyltransferases, and chromatin remodeling factors, creating a
protein complex that regulates gene expression. If the promoter region is methylated,
the corresponding gene’s expression is suppressed due to its’ inability to recognize
transcription factors (Gnyszka et al., 2013).
5-azacytidine (AZA) is the most commonly used DNA methyltransferase (DNMT)
inhibitors. Once incorporated into the genome, 5-AZA disrupts the interaction between
DNA and DNMTs through nitrogen, instead of carbon, in the 5-position of the modified
pyrimidine (Gnyszka et al., 2013). The enzyme remains covalently bound to DNA and
its DNMT, thus blocking its function. Additionally, the covalent protein adduction also
compromises the functionality of DNA and triggers DNA damage signaling, resulting in
the degradation of trapped DNMTs. As a result, further methylation of cytosine residues
is inhibited, causing the passive loss of cytosine methylation in daughter cells
(Stresemann and Lyko, 2008).
As previously mentioned, the vast majority of cells subjected to direct
reprogramming conditions are trapped in an intermediate state that is characterized by
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the downregulation of somatic genes, maintenance of viral transgene expression,
incomplete reactivation of pluripotent genes, inability to form chimeras, and persistent
DNA hypermethylation. Mikkelsen et al., (2008) demonstrated that these partially
reprogrammed cells can be coaxed to undergo complete reprogramming by treatment
with 5-AZA. Furthermore, treatment with 5-AZA was also shown to improve the number
of ESC-like colonies by 4-fold (Mikkelsen et al., 2008).
Histone Deacetylase Inhibitors
Acetylation plays an important role in nucleosome assembly and chromatin
folding. Acetylation favors an open chromatin structure by interfering with the
interactions between nucleosomes and releasing the histone tails from the linker DNA.
Chromatin regions that are marked by lysine acetylation catalyzed by Histone Acetyltransferase (HATs) are generally actively transcribed, whereas regions that are bound
by Histone Deacetylases (HDACs) bear deacetylated lysines and are inactive
(Shahbazian and Grunstein, 2007; Kretsovali et al., 2012).
HDAC inhibitors (HDACis) are small molecules that inhibit the activities of
HDACs, thus playing a major role in epigenetic regulation. Consequently, HDACis have
been widely utilized in nuclear reprogramming. Trichostatin A (TSA) and valproic acid
(VPA) are among the most commonly used HDACis, and their role as an effective
facilitator of nuclear reprogramming has been well documented. Huangfu and
colleagues (2008a) demonstrated the ability to generate iPSC in the absence of c-myc
by substituting it for VPA. Using the pluripotency factors Oct-4, Sox-2, and Klf-4 and
VPA, they were not only able to reprogram primary human fibroblast cells into iPSC, but

28

they were also able to increase the number of iPSC colonies by 50-fold. In another
study by Huangfu and colleagues (2008b), it was shown that the combination of Oct-4,
Sox-2, and VPA was sufficient to reprogram somatic cells at an efficiency similar to that
of three factor reprogramming. It should be noted that other combinations of two factors
did not yield any iPSC, even in the presence of VPA, suggesting that Oct-4 and Sox-2
are indispensable in reprogramming human fibroblasts in the context of VPA treatment.
That being said, mouse embryonic fibroblasts (MEFs) treated only with VPA exhibited
an upregulation of ESC-specific genes, while MEF-specific genes were downregulated.
This suggests that VPA may support a predisposition towards an ESC-like state.
Furthermore, the genome-wide acetylation induced by VPA and other HDACis could
allow MEFs to adopt a relaxed chromatin structure that facilitates the binding of
ectopically expressed transcription factors or downstream secondary factors (Feng et
al., 2009).
Other Small Molecules
Histone lysine methylation plays a key role in the organization of chromatin
domains and the regulation of gene expression; however, aberrant expression of
histone lysine methyltransferasees (HMTases) like G9a has been linked to tumor
development. G9a is a H3K9 methyltransferase, which is localized exclusively in
euchromatic regions. It functions to repress gene activity by inducing local H3K9me2
and H3k9me3 at target promoters (Kubicek et al., 2007). In addition to inducing di- and
tri-methylation of H3K9, G9a methylates K373 of p53, a tumor suppressor.
Overexpression of G9a results in the inactivation of p53, which is implicated in over
50% of cancers (Huang et al., 2010). Studies have shown that knockout of G9a inhibits
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cancer growth (McGarvey et al., 2006; Kondo et al., 2008), leading researchers to
explore G9a inhibition as a potential approach for cancer treatment.
BIX-01294 has been identified as a small-molecule inhibitor of G9a. BIX-01294
does not compete with the cofactor S-adenosyl-methionine, and is highly selective for
G9a. Importantly, BIX-01294 is biologically active in reducing H3K9me2 levels at
several G9a target genes, thereby allowing for the transient reversal of this repressive
mark in vitro (Kubicek et al., 2007). Among the many genes G9a HTMase regulates is
the pluripotency gene, Oct-4. The quest to generate iPSC efficiently and without viral
genome integration lead Shi et al (2008a) in search of a chemical cocktail that would
allow reprogramming of somatic cells in chemically defined conditions. In this study,
neural progenitor cells (NPC), which endogenously express Sox-2 (Blelloch et al.,
2006), were transduced with only Oct-4 and Klf-4 and were successfully reprogrammed
to iPSC. They found reprogramming to be greatly enhanced by the presence of BIX01294. Furthermore, BIX-01294 was shown to enable reprogramming of NPC
transduced with c-Myc, Klf-4, and Sox-2, in the absence of Oct-4 ectopic expression. In
this particular system, BIX-01294 seemed to compensate for the lack of Oct-4
overexpression (Shi et al., 2008a). In a follow-up study by Shi and colleagues, they
aimed to assess if a similar strategy could be used to find small molecules that can
replace viral transduction to obtain iPSC from a general cell line, mouse embryonic
fibroblasts (MEF), in which none of the transcription factors deemed essential for
reprogramming, Oct-4, Sox-2, and Klf-4, are expressed. They found that a combination
of BIX-01294 and Bayk8644, a L-channel calcium agonist, was effective at enabling the
generation of iPSC from MEF transduced with only Oct-4 and Klf-4 (Shi et al., 2008b).
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Their interest in Bayk8644 stems from the fact that it exerts its effects upstream in cell
signaling pathways and does not directly cause epigenetic modifications; therefore, it
can likely be exploited to induce reprogramming in a more specific manner than
molecules acting directly at the epigenetic level causing DNA or histone modification
(Shi et al., 2008b). Activation of L-type calcium channels by different agonists, including
Bayk8644, has been shown to induce intracellular signaling through CREB activation,
sacoplasmic reticulum calcium release, and change in cAMP activity. Furthermore, it
has been suggested that calcium may play a role in the control of mESC proliferation
(Heo et al., 2006). However, Shi et al (2008b) observed no change in proliferation when
mESC were treated with Bayk8644 alone or in combination with BIX-01294. Treatment
of MEF with Bayk8644 alone or in combination with BIX-01294 did not induce Sox-2
expression either, making it rather interesting that Bayk8644 improves reprogramming
efficiency. While further work is needed to dissect the exact mechanism by which
Bayk8644 improves the reprogramming process, it is interesting to find that a small
molecule with activity in signaling pathways that have not been previously linked to
reprogramming can significantly enhance its efficiency (Shi et al., 2008b). To date, it is
the only small molecule of its type to show an effect of reprogramming, as most of the
other small molecules identified appear to directly modify the epigenetic status of the
cell: BIX-01294 (Shi et al., 2008a), VPA (Huangfu et al., 2008), and 5-AZA (Mikkelsen et
al., 2008). Because Bayk8644 does not reprogram on its own but requires the
presence of BIX-01294 to exert its effects, this suggests that cells that are already
undergoing a form of reprogramming, may be more susceptible to its effect, making it
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possible to reprogram the target cell in a more specific manner, without impacting
healthy cells systemically, as direct epigenetic modifier might (Shi et al., 2008b).
Small molecules are also employed to target specific signaling pathways that
coincide with the pluripotent state. The role Leukemia Inhibitory Factor (LIF) and Bone
Morphological Protein (BMP) play in the self-renewal of murine ESC has been well
established (Niwa et al., 1998); therefore, it was surprising to discover that mESCs
could sustain their identity in the absence of LIF and BMP. Chen and colleagues
(2006) identified a synthetic small molecule known as Pluripotin, which enabled mESC
to maintain long-term self-renewal under feeder-, serum-, and LIF-free conditions.
Pluripotin inhibits two endogenous differentiation-inducing proteins, Ras GTPaseactivating protein (RasGAP) and ERK1 (also known as MAPK3), thus allowing
pluripotency to be sustained without the use of exogenous factors to activate
pluripotency-associated pathways. The identification of Pluripotin revealed a
fundamental strategy for maintaining stem cell self-renewal through the inhibition of
endogenous differentiation mechanisms, and explained how combining the activation of
differentiation-inducing pathways with the modulation of other pathways can sustain
self-renewal by effectively balancing out the differentiation activity of stem cells (Zhang
et al., 2012). Similarly, PD0325901, a mitogen activated protein kinase/ERK kinase
(MEK) inhibitor, and CHIR99021, a glycogen synthase kinase-3 (GSK3) inhibitor, have
also been shown to facilitate the maintenance of mESC without the need for feeder cells
or exogenous cytokines (Buehr et al., 2008). Inhibition of both the MEK and GSK3
pathways eliminates the need for LIF and BMP in mESCs. Stimulation of the ERK
signaling pathway triggers the transition from pluripotency to lineage-commitment
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(Kunath et al.,2007); therefore, by blocking the ERK signaling pathway, lineagecommitment is inhibited and the ground state of ESC self-renewal is maintained (Ying et
al., 2008).
Increased understanding of signaling pathways and their role in cellular identity
has greatly advanced iPSC technology. Although the strategy developed by Takahashi
and Yamanaka for generating iPSC has enormous therapeutic potential, it is not an
infallible technique, and, despite substantial progress in recent years, a number of
challenges remain. Reprogramming remains a largely inefficient and non-specific
process, with efficiencies of transduced cells becoming fully reprogrammed iPSCs lower
than 0.01% (Takahashi et al., 2007; Yu et al., 2007; Hasegawa et al., 2010). The
majority of transduced cells become trapped in a pre-iPSC state that is characterized by
the downregulation of somatic cell marker genes, incomplete reactivation of
pluripotency genes, maintenance of viral expression, and the inability to form chimeras.
To achieve complete reprogramming, DNA methylation, histone modification, and
chromatin structure need to mimic that of the embryonic environment. The introduction
of key transcription factors (Oct-4, Sox-2, Klf-4, c-myc) initiate a number of complex
processes that cooperatively function to reboot the epigenetic state of the somatic cell
type. C-myc is believed to loosen the tight chromatin structure characteristic of somatic
cells, which allows Oct-4 and Sox-2 to co-bind their target genes to launch the
pluripotent network (Takahashi and Yamanaka, 2006; Wernig et al., 2008). Among
these targets are a group of genes that encode for epigenetic factors that participate in
the maintenance of self-renewal and pluripotency (Loh et al., 2006). Several studies
have shown that small molecules can improve reprogramming when combined with
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conventional reprogramming factors (Huangfu et al., 2008; Mikkelsen et al., 2008; Shi et
al., 2008b). The relief of repression on key pluripotency genes such as Oct-4 and
Nanog may allow an earlier induction of self-renewal and pluripotency (Feng et al.,
2009). Similarly, Silva and colleagues (2008) demonstrated that partially reprogrammed
cells can be coaxed out of this state and transition to fully reprogrammed iPSCs by
treatment with the chemicals PD0325901 and CHIR99021 to inhibit MEK and GSK3,
respectively. These chemical inhibitors could potentially induce a global permissive
epigenetic landscape similar to ESCs by inducing epigenetic changes that promote the
active transcriptional state and facilitating the erasure of repressive epigenetic features.
The combination of events may provide exogenous reprogramming factors and
secondarily-induced transcription factors greater access to downstream target genes.
Therefore, genetic factors and small molecules may synergiscally modify epigenetic
features to activate the pluripotent transcriptional network to enhance reprogramming
(Feng et al., 2009).

Conclusion
In 2006, Shinya Yamanaka made a groundbreaking discovery that would
ultimately win him the Nobel Prize in Physiology and Medicine just 6 years later. The
discovery of iPSC represents the culmination of over 60 years of research, which began
by asking the simple question: “is cell fate irreversibly fixed as cells become more
specialized?” The progression from nuclear transfer in frogs to the generation of
patient-specific iPSC echoes scientists’ expanding knowledge of the molecular
machinery that regulate cell fate. Collectively, these studies prove that a differentiated
cell can be reverted back to earlier state. The resetting of the somatic cell nucleus to an
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embryonic state involves several complex mechanisms, and, despite an increased
understanding of reprogramming mechanisms, much is still to be learned before its full
potential can be harnessed. Nevertheless, research in the field of iPSC is steadfast and
progress is continuously being made.
Studies have revealed that epigenetics play a crucial role in nuclear
reprogramming. Resistance to reprogramming is largely attributed to the phenomenon
of epigenetic memory that cells retain throughout numerous cell divisions. As cells
become more differentiated, they acquire epigenetic marks that make their nuclei
increasingly resistant to reprogramming (Pasque et al., 2011). However, modulations of
the epigenetic processes that accompany nuclear reprogramming may facilitate the
conversion to an epigenetic landscape that is more permissive to reprogramming.
Various tools have been employed to help cells overcome this reprogramming
roadblock, including the use of small molecules. Several chemical compounds that
control epigenetic enzymes, such as HDAC, HMT, DNMT, and histone demethylase
(HDM) have been shown to improve reprogramming efficiency, or even replace the
need to use certain transcription factors (Zhang et al., 2012). This is especially
promising for the clinical application of iPSC as there are serious concerns regarding
the safety of current genetic approaches to nuclear reprogramming, as well as
traditional culture systems that are used to maintain iPSC. Small molecules provide an
attractive approach to addressing these challenges, as they offer a number of
compelling advantages. First, the biological effects of small molecules are typically
rapid, reversible and dose-dependent, allowing precise control over specific outcomes
by fine-tuning their concentrations and combinations. Second, the structural diversity
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that can be provided by synthetic chemistry allows the functional optimization of small
molecules. Third, compared with genetic interventions, the relative ease of the handling
and administration of small molecules make them more practical for in vitro and in vivo
applications, and for further therapeutic development (Zhang et al., 2012).

36

CHAPTER III
EFFECT OF SMALL MOLECULE TREATMENT ON EXPRESSON OF
PLURIPOTENCY GENES IN BOVINE FETAL FIBROBLAST CELLS
Introduction
Successful reprogramming of somatic cells towards pluripotency requires the
epigenetic marks characteristic of the differentiated cell type first be erased in order to
inactivate the somatic cell program and activate the embryonic program. However, the
majority of cells subjected to reprogramming conditions become trapped in a partially
reprogrammed state that is characterized by the downregulation of somatic cell marker
genes, incomplete reactivation of pluripotency genes, maintenance of viral expression,
and the inability to form chimeras. To achieve complete reprogramming, DNA
methylation, histone modification, and chromatin structure need to mimic that of the
embryonic environment. Several small molecules, affecting specific signaling pathways
and/or chromatin modifications, have been shown to improve both the kinetics and
efficiency of reprogramming (summarized in Table 2.1). In pharmacology, a small
molecule is defined as low molecular weight (<900 Daltons) organic bioactive
compounds that may help regulate a biological process. These chemical modifiers aid
in overcoming the “roadblocks” encountered during the reprogramming process by
inducing the necessary epigenetic modifications needed to silence the somatic cell
genome and completely reactivate the ESC genome. Chemical treatment of cells prior
to reprogramming can remodel the epigenetic landscape of the somatic cell type to be
more like that of ESC by removing the repressive epigenetic marks and relaxing
chromatin structure to allow the reprogramming factors easier access to target genes.
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In the decade since Takahashi and Yamanaka’s (2006) groundbreaking discovery,
much effort has been made to better understand the molecular circuitry permitting the
generation of iPSC in the hopes of improving this reprogramming method.
Reprogramming by defined factors is an ineffective process, with efficiencies of
transduced cells becoming fully reprogrammed iPSC lower than 0.01% (Takahashi et
al., 2007; Yu et al., 2007; Hasegawa et al., 2010). Furthermore, safety concerns
regarding the use of exogenous genes and the method of delivering these
reprogramming factors, as well as technical and logistical challenges have hindered
clinical applications of iPSC. Scientists tackled these issues with steadfastness, and a
number of genetic factors, chemical inhibitors, and signaling molecules have been
shown to either promote or enhance reprogramming. Concerns over genome
modification through exogenous sequences were largely resolved by the introduction of
new delivery methods, which included the use of episomal plasmids (Yu et al., 2009) or
excisable expression systems (Soldner et al., 2009), recombinant cell-penetrating
reprogramming proteins (Kim et al., 2009; Zhou et al., 2010) and reprogramming
mRNAs (Warren et al., 2010; Yakubov et al., 2010) or microRNAs (Anokye-Danso et al.,
2011; Miyoshi et al., 2011). Although, genetic methods have been widely used to
address these issues, a chemical approach offers many advantages. First, the
biological effects of small molecules are typically rapid, reversible and dose-dependent,
allowing precise control over specific outcomes by fine-tuning their concentrations and
combinations. Genetic approaches, on the other hand, involve permanent genome
modifications with associated problems of tumorigenicity and other irreversible,
unintended consequences. Second, the structural diversity that can be provided by
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synthetic chemistry allows the functional optimization of small molecules. Whereas
biological reagents are best suited for targeting extracellular components, small
molecules are cell-permeable and, therefore, have the potential to target every class of
macromolecule in the cell. Third, compared with genetic interventions, the relative ease
of the handling and administration of small molecules make them more practical for in
vitro and in vivo applications, and for further therapeutic development (Zhang et al.,
2012). Because of the advantages, interest in utilizing small molecules in stem cell
biology and regenerative medicine has significantly heightened. Table 3.1 summarizes
the growing number of small molecules that have been identified to maintain selfrenewal potential of stem cells, to induce lineage differentiation, and to facilitate
reprogramming either by increasing efficiency or by replacing genetic reprogramming
factors. Identification of novel small molecules compounds that affect cell fate and
increased understanding of the nuclear reprogramming process lead Hou et al. (2013)
to report the first-ever all chemical generation of mouse iPSC from MEF cells. The
Chemically-induced Pluripotent Stem Cells (CiPSCs) were induced through a very
complicated procedure with 3-step compound treatment shown in Figure 3.1. After a
year of screening 10,000 compounds, they concluded that a cocktail of seven small
molecules was capable of cell fate reprogramming. The seven small molecule cocktail,
known as “VC6TFZ”, is comprised of VPA, CHIR99021, 616452, Tranylcypromine,
Forskolin (FSK), 2-methyl-5-hydroxytryptamine (2-Me-5HT), and D4476. Hou et al.
(2013) identified this potent cocktail by first generating iPSC using the Oct-4 gene in
combination with CHIR99021, 616452, and Tranylcypromine.
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Next, they screened different chemical substitutes for Oct-4 using a Oct-4 promoterdriven GFP expression system. After screening 10,000 compounds, they concluded
FSK, 2-Me-5HT, and D4476 could substitute for Oct-4. VC6TF treatment yielded some
GFP-positive cell clusters, however neither Oct-4 nor Nanog were detectable in these
cells, indicating incomplete reprogramming. They identified one final chemical, 3deazaneplanocin (DZNep), to be critical later in the reprogramming process for
activating endogenous Oct-4. They designed CiPSC protocol including 3 steps as
follows: (a) MEF cells were cultured in mESC medium containing VC6FT for 16–20
days; (b) cells were cultured in the medium with VC6FTZ for 12–20 days; (c) cells were
cultured in mESC medium containing 2i (PD0325901 and CHIR99021) for 1 week (Hou
et al., 2013).

Figure 3.1 Schematic diagram illustrating direct iPSC reprogramming from
MEF using only small molecules. Hou et al.,(2013) reported that CiPSC
generation from MEF was carried out in three steps of 16-20 days in VC6TF
treatment, and then 12-20 days in VC6TFZ followed by the application of two
MEK and GSK3-β inhibitors, known as “2i”, to finalize chemical reprogramming.
Using a doxycycline (DOX)-inducible GFP-Oct-4 expression screening system,
ectopic GFP-Oct-4 expression was induced during the first round, followed by
DOX withdrawal and small molecule treatment.
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Chemical-only reprogramming is a long, multi-step, sequence-dependent
process characterized by a unique intermediate state. The cells at this intermediate
state have a strong resemblance to embryo-derived extraembryonic endoderm (eXEN)
cells (Zhou et al., 2010). eXEN cells are derived from primitive endoderm cells in late
blastocyst stage embryos and continue to propagate in culture while retaining their
ability to contribute to extraembryonic cell lineage after injection into blastocysts (Kunath
et al., 2007). The intermediate cells of chemical reprogramming, designated as
chemically-induced XEN (CeXEN) cells, express Gata4, Gata6, Sox17, Sox7, and Sall4,
and also possess the ability to contribute to the extraembryonic cell lineages in chimeric
embryos. Moreover, both eXEN and CeXEN cells are competent to be reprogrammed to
the pluripotent state by the second step of chemical reprogramming cocktail, indicating
their stringent similarity in their cell biological characteristics. It has been shown that the
knockdown of the endoderm-associated TFs such as Gata6 compromises the first step
of chemical reprogramming, whereas its overexpression with additional TF Sall4
replaces some components of the first step chemical reprogramming cocktail,
confirming the functional importance of the XEN-like state as an intermediate (Zhou et
al., 2010).
XEN-like state is an intermediate of the chemical reprogramming, but not of TFmediated reprogramming. Some small molecules have demonstrated the ability to
replace individual Yamanaka factors; however, no single combination of small
molecules is capable of replacing them all. Intrigued by this dubious discovery, Shu et
al. (2013) performed many studies to discern the chemical-based reprogramming
mechanism. They proposed a new “Seesaw” model in which the pluripotent state is a
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precarious balancing equilibrium that results from continuous mutual competition
between rival lineage specification forces. Pluripotency-inducing reprogramming factors
have been identified primarily from pluripotency-associated factors in ESC; however,
pluripotency can be induced with lineage specifiers that suppress ESC identity using
pluripotency rivals, most of which are not enriched in ESCs. To that end, Shu et al.
(2013) reported that Oct-4 and Sox-2 can be replaced by lineage specifiers that are
involved in mesendodermal (ME) and ectodermal (ECT) specification, respectively. Oct4 and its substitutes attenuated the elevated expression of a group of ECT genes,
whereas Sox-2 and its substitutes curtailed a group of ME genes during reprogramming.
Moreover, they found that the two counteracting lineage specifiers could synergistically
induce pluripotency in the absence of both Oct-4 and Sox-2 (Shu et al., 2013). Based
on these findings, they concluded that chemical-based reprogramming is mediated by
the counteracting lineage specifier compounds, VC6FTZ.
Insight into the mechanisms that govern nuclear reprogramming has propelled
the advancement and improvement of reprogramming strategies. Therefore, we sought
to assess the genetic and epigenetic effects of pre-treatment with small molecules on
the core pluripotency-determining transcription factors, Oct-4, Nanog, and Sox-2. In
this first study, we measured the effect of small molecule treatment on Oct-4, Nanog,
and Sox-2 transcript expression in bovine fetal fibroblast (BFF) cells.
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Materials and Methods
Experiment 1 Experimental Design
In the present study, we assessed the effect of pre-treatment with small molecule
inhibitors on the expression of Oct-4, Nanog, and Sox-2 in BFF cells. BFF cells were
allowed to expand in culture before being split evenly into two groups. Cells in the
control group were cultured in complete culture medium (DMEM + 10% FBS + 1% P/S),
whereas cells in the treatment group were cultured in complete culture medium
supplemented with 0.5mM PD0325901, 3mM CHIR99021, and 1.8mM NuP0178 for the
duration of 7 days. On day 7, mRNA was isolated from control and treatment cell
cultures for gene expression analysis. Quantitative (qRT-PCR) was performed to
measure transcript levels for Oct4, Nanog, and Sox-2 in control and treatment BFF
cells.
Experiment 2 Experimental Design
To explore what, if any, effects a longer period of treatment with PD325901,
CHIR99021, and NuP0178 has on Oct-4, Nanog, and Sox-2 expression in BFF cells, we
extended the culture period to 14 days. Using the same design and procedures as
Experiment 1, control and treatment cells were cultured in their respective culture
system for a total of 14 days. On day 14, mRNA was isolated from both control and
treatment cell cultures for gene expression analysis. Quantitative (qRT-PCR) was
performed to measure transcript levels for Oct4, Sox2, Nanog in control and treatment
BFF cells.
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Establishment of Cell Lines and Maintenance
Target cell lines were obtained from previously isolated primary cultures.
Primary cultures of fibroblast cells were established from bovine fetuses approximately
50 days old according to protocol (Giraldo et al., 2009; Coley, 2010). BFF cells were
cultured in complete culture medium composed of Dulbecco’s Modified Eagle Medium
(DMEM) with high glucose, 10% fetal bovine serum (FBS), and 1%
penicillin/streptomycin (P/S). Once cells reached 80% confluency, cultures were
passaged by releasing cells with trypsin (0.25%). BFF cells were then resuspended in
DMEM supplemented with 10% bovine calf serum (CS) and 10% dimethyl sulfoxide
(DMSO) for cryopreservation. Cryovials containing approximately 1,000,000 BFF cells
suspended in solution were cooled at 1°C/min until reaching -80°C before storage in
liquid nitrogen.
BFF cells were thawed as needed at room temperature for 30 sec, followed by
submersion in a 37°C water bath. Cells were then washed in complete culture medium
and seeded at a density of 0.7 x 106 into 25-cm2 flasks and cultured under 5% CO2 and
90% humidity at 37°C. Because the experimental procedure required a high volume of
cells, BFF cells were expanded through repeated passaging until a sufficient number of
cells were obtained prior to each experiment.
Treatment with Small Molecules
Chemical treatment consisted of 3 small molecule inhibitors (3i): PD0325901
(Stemgent,Lexington, MA, Cat.no. 04-0006), a mitogen activated protein kinase/ERK
kinase (MEK) inhibitor; CHIR99021 (Stemgent, Lexington, MA, Cat.no. 04-0004), a
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glycogen synthase kinase-3 (GSK3) inhibitor; and NuP0178 (NuPotential, Baton Rouge,
LA), a G9a histone methyltransferase inhibitor. A 10mM stock solution of each inhibitor
was prepared by dissolving the crystalline solid in DMSO. 3i+ media was prepared by
diluting each stock into complete culture medium (DMEM, 10% FBS, 1% P/S) to a
concentration of 0.5µM PD0325901; 3µM CHIR99021; 1.8µM NuP0178. The
concentrations of CHIR99021 and PD0325901 utilized were consistent with previous
studies (Yu et al., 2011) and NuP0148 concentration was estimated due to its recent
development and concentration evaluation experiments carried out by NuPotential, LLC.
Once BFF cells were expanded to an adequate quantity, trypsin (0.25% EDTA)
was added to confluent cultures of BFF cells to disaggregate cells adherent to the flask,
which were then counted using a hemocytometer. Cells were then divided evenly into
treatment and control groups, approximately 2.5 x 106 cells per group. Control cells
were resuspended in complete culture medium and split evenly between three 25-cm2
flasks (approximately 0.7 x 106 per flask). Similarly, treatment cells were resuspended
in 3i+ media and split evenly between three 25-cm2 flasks (approximately 0.7 x 106 per
flask). All flasks were then placed in 37°C incubator with 5% CO2 and 90% humidity.
Media was changed every 1-2 days, and cells were passaged as needed.
Isolation of mRNA
On days 7 and 14, both treatment and control cells were harvested by
trypsinization and washed in 1 ml of Dulbecco’s Phosphate Buffered Solution (DPBS)
with Ca+2 and Mg+2. Cells were pelleted by centrifugation, and the cell pellet was placed
in -80°C freezer for later use. mRNA was isolated from both treatment and control cells
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using Dynabeads® mRNA Direct™ Kit (Invitrogen Dynal As, Oslo, Norway, Cat.no.
610.11/610.12) as described previously by Wrenzycli et al (2001). Frozen cell pellets
were removed from -80°C freezer, and 1.25 ml of lysis/binding buffer (100 mM Tris-HCl
(pH 7.5), 500 mM LiCl, 10 mM EDTA (pH 8), 1% lithium dodecylsulfate (LiDS), and 5
mM dithiothreitol (DTT)) was immediately added to the frozen cell pellet. Cell
suspension was repeatedly passaged through a pipette tip to facilitate lysis; however
because samples contained more than 5 x 105 cells, a DNA-shear step was also
performed. DNA was sheared by forcing the lysate through using a 21 gauge needle
five times to obtain complete cell lysis. Next, the sample lysate (1.25 ml) was added to
250 µl of pre-washed Dynabeads® Oligo(dT)25 and resuspended completely. The beadlysate mixture was incubated for 5 min on a rotating mixer to allow the polyA tail of the
mRNA to hybridize to the oligo (dT)25 on the beads. The beads were separated from
the mix using a Dynal MPC-E-1 magnetic separator. The beads/mRNA complex was
then washed twice in 1 ml of Washing Buffer A (10 mM Tris-HCl (pH 7.5), 150 mM LiCl,
1 mM EDTA, and 0.1% LiDS), followed by two washes with 1 ml of Washing Buffer B
(10 mM Tris-HCl (pH 7.5), 150 mM LiCl, and 1 mM EDTA). mRNA was eluted from the
beads by adding 25 µl of 10 mM Tris-HCl (pH 7.5) and incubating for 2 min at 75°C.
Immediately after incubation, tubes were placed in the Dynal MPC-E-1 magnetic
separator to separate the beads from the mRNA. The supernatant containing the
mRNA was transferred to a new RNase-free tube and placed on ice for succeeding use
in reverse transcription.
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Reverse Transcription
The freshly-isolated mRNA was reverse transcribed into cDNA in a total volume
of 25 µl using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Inc., Hercules, CA,
USA, Cat.no. 1708890). Each 25 µl iScript RT Reaction mix consisted of 12.5 µl of
sample mRNA, 1 µl of reverse transcriptase, 4 µl of 5X iScript reaction mix, and 7 µl of
nuclease-free H2O. The reaction was conducted at 25˚C for 5 min, 42˚C for 30 min, a
denaturation step of 85˚C for 5 min, and a final holding temperature of 4˚C.
Quantitative Real-Time PCR
Our laboratory has previously analyzed BFF cells for Oct-4, Nanog, and Sox-2
expression, thus we have validated the specificity of primers for PAP, Oct-4, Nanog,
and Sox-2 (Coley, 2010). All primers were designed from bovine gene sequences using
the Beacon Designer 4.0 (PREMIER Biosoft International) (Table 3.2), and were diluted
to 10 mM concentration. cDNA was amplified using SsoFast™ EvaGreen supermix (BioRad Laboratories, Inc., Hercules, CA, USA). The total 20 μl real time PCR mix consisted
of 2 μl of cDNA, 10 µl of SsoFast™ EvaGreen Supermix, 6 μl of nuclease-free water,
and 1 μl of forward and reverse primer pairs (10 mM) for each gene. Within each qRTPCR plate setup, reactions for the reference gene and each gene of interested were
performed using the calibrator cDNA, the sample cDNA, and a no template negative
control. Oct-4, Nanog, and Sox-2 expression levels in all samples was quantified using
the Bio-Rad CFX Connect™ Real-Time PCR Detection System. The PCR program
used for the amplification of all genes consisted of a denaturing cycle of 30 sec at 95°C;
40 cycles of PCR (95°C for 5 sec and 55°C for 20 sec); ); a melting curve analysis
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Table 3.1. Primer Sets for qRT-PCR for Gene Expression Analysis

Accession
Number

Gene

Primers

Amplicon
Length

Oct-4

NM174580

Sense GGTTCTCTTTGGAAAGGTGTTC
Antisense ACACTCGGACCACGTCTTTC

223

Nanog

DQ069776

Forward AATTCCCAGCAGCAAATCAC
Reverse CCCTTCCCTCAAATTGACAC

215

Sox-2

NM001105463

Sense AGGACTGAGAGAAAGAAGAAGAG
Antisense AAGAAAGAGGCAAACTGGAATC

164

PAP

X63436

Sense AAGCAACTCCATCAACTACTG
Antisense ACGGACTGGTCTTCATAGC

169

which consisted of 95°C for 5 sec, 65°C for 1 min, followed by continuous acquisition at
97˚C, with 5 acquistions per ˚C; and a final holding temperature of 4°C.
Data was quantified using the method for relative quantification in qRT-PCR
described by Pfaffl (2001). Values are reported as relative transcription or the n-fold
difference relative to a calibrator. A mixture of cDNA from BFF cells at multiple
passages was used as a calibrator for all of the target genes. PAP was used as the
internal reference gene. The threshold cycle value of the reference gene was used to
normalize the target gene signals in each sample. The amount of target transcripts
relative to the calibrator was calculated using the following equation: n-fold difference =
Efficiency Target GeneΔCTT/ Efficiency Reference GeneΔCTR, where an efficiency value
of two was assumed. The ΔCTT (for the target gene) value was calculated by
subtracting the sample CT value of the target gene from the calibrator CT value of the

48

target gene. The ΔCTR (for the reference gene) value was calculated by subtracting the
sample CT value of the reference gene PAP from the calibrator CT value of the
reference gene. Therefore, all target abundance levels were expressed as n-fold
differences relative to a calibrator and normalized to the reference gene in order to
compensate for PCR variations between runs.
Statistical Analysis
In this experiment, a completely random design with repeated measures was
employed to assess any effect treatment with 3i+ media had on Oct-4, Nanog, and Sox2 gene expression in BFF cells over time. The PROC MIXED with repeated measures
analysis with autoregression of order one covariance was used in SAS statistical
software to determine any statistical differences in relative gene expression between
treatment and control groups over time.

Results
The values corresponding to the relative expression of Oct-4, Nanog, and Sox-2
in untreated BFF cells and BFF treated with 3i+ media at day 7 and day 14 are reported
in tables 3.3 and 3.4, respectively. Statistical analysis comparing Oct-4, Nanog, and
Sox-2 expression levels in treatment and control groups revealed no significance
difference in gene expression between groups at either day 7 or day 14. Likewise, time
did not have a significant effect on Oct-4, Nanog, and Sox-2 transcript levels in BFF
cells cultured in the presence of the small molecule inhibitors, CHIR99021, PD0325901,
and NuP0178. Therefore, there was no significant effect of the treatment and time
interaction.
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Table 3.2. Oct-4, Nanog, and Sox-2 Relative Expression in Treatment and
Control BFF Cells on Day 71

Sample

Oct-4

Nanog

Sox-2

BEZ 2 P4 CON (1)

20311.37

8364.13

474.41

BEZ 2 P4 TRMT (1)

14.83

1.75

4.59

BEZ 3 P4 CON

0.2793

0.9931

0.0151

BEZ 3 P4 TRMT

1.68

0.1199

0.0100

BEZ 2 P4 CON (2)

76.64

21.26

9.71

BEZ 2 P3 TRMT (2)

4.41

0.3686

0.1550

BEX 4 P3 TRMT

235.57

11.88

8.28

BEX 1 P3 CON

1.56

0.6242

0.0813

BEX 3 P4 CON (2)

3.92

2.53

0.1708

1The

relative expression of Oct-4, Nanog, and Sox-2 at day 7 was measured in five BFF
cell lines, designated as BEZ 2, BEZ 3, BEX 4, BEX 1, and BEX 3. BEZ 2 served as a
biological replicate, denoted as BEZ 2 (1) and BEZ 2 (2).
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Table 3.3. Oct-4, Nanog, and Sox-2 relative expression in treatment and control BFF
cells on day 142

Sample

Oct-4

Nanog

Sox-2

BEZ 2 P4 TRMT

209.39

51.63

30.70

BEZ 3 P5 CON

0.8409

0.9593

10.3388

BEZ 3 P5 TRMT (1)

1.23

0.6690

0.6690

BEX 4 P6 TRMT

9.32

2.16

0.5946

BEZ 3 P5 TRMT (2)

7.11

8.51

4.41

Table 3.3. Oct-4, Nanog, and Sox-2 relative expression in treatment and control BFF
cells on day 142
BEZ 2 P5 CON
51063.33
5404.70
14066.74

2The

relative expression of Oct-4, Nanog, and Sox-2 at day 14 was measured in three
BFF cell lines, designated as BEZ 2, BEZ 3, and BEX 4. BEZ 3 served as a biological
replicate, denoted as BEZ 3 (1) and BEZ 3 (2).

Discussion
The small molecule inhibitors, CHIR99021 and PD325901, have been widely
used as tools to facilitate the generation and maintenance of iPSC (Li et al., 2009; Lin et
al., 2009; Hanna et al., 2010; Zhou et al., 2010). In these cases, CHIR99021 and
PD325901 aid in overcoming the “roadblocks” encountered during the reprogramming
process by inducing the necessary epigenetic modifications needed to silence the
somatic cell genome and completely reactivate the ESC genome. Interestingly,
CHIR99021 and PD0325901 have been found capable of maintaining mESC in culture
without the need of feeder cells or exogenous cytokines (Buehr et al., 2008). Inhibition
of both the GSK3 and MEK pathways by CHIR99021 and PD0325901, respectively,
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eliminates the need for LIF and BMP in mESCs. Stimulation of the ERK signaling
pathway triggers the transition from pluripotency to lineage-commitment (Kunath et al.,
2007); therefore, by blocking the ERK signaling pathway, lineage-commitment is
inhibited and the ground state of ESC self-renewal is maintained. Suppression of ERK
activation is achieved with the addition of PD0325901, and together with CHIR99021,
have shown to be sufficient to sustain efficient ESC self-renewal (Ying et al., 2008).
We have previously shown that some sources of ASC, including BFF, express
transcripts for the key pluripotency genes, Oct-4, Nanog, and Sox-2 (Coley, 2007).
While these cell types’ differentiating and self-renewing capabilities are far less robust
than that of ESC, we reasoned that the same system involved in promoting the
pluripotent state in mESC and hESC would similarly work to maintain, or possibly
enhance, the less differentiated state characteristic of BFF cells. While there was no
significant increase in Oct-4, Nanog, or Sox-2 relative gene expression detected
between control and treatment samples at either day 7 or day 14, it is important to note
that there was no significant decrease in the relative expression of these transcripts
over time either. Typically, pluripotent gene expression in ASC decreases as passage
number increases (Tsai and Hung, 2012), yet the extended culture period and
consequential passaging required to maintain cells in culture for an extended period of
time did not result in a significant decrease in Oct-4, Nanog, or Sox-2 expression.
This is an opportune time to point out that not all researchers agree that
CHIR99021 and PD032591 facilitate somatic cell reprogramming. Several studies
dissecting the mechanism of action of CHIR99021 and PD032591 in facilitating and
enhancing nuclear reprogramming have been previously discussed in detail (Li et al.;
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Buehr et al., 2008; Shi et al., 2008b; Ying et al., 2008; Li et al., 2009; Nichols and Smith,
2009; Hanna et al., 2010; Zhou et al., 2010; Tsutsui et al., 2011), and while there is no
shortage of evidence supporting this, it is imperative to discuss those results conflicting
with this notion. As previously discussed, the Wnt signaling pathway is postulated to
play an important role in self-renewal in both human and mouse ESC. When the
canonical Wnt signaling pathway is stimulated, β-catenin translocates to the nucleus
where it interacts with Tcf/Lef proteins to activate target genes. With regards to nuclear
reprogramming, the Wnt-β-catenin pathway is thought to help reestablish pluripotency
specifically by alleviating the inhibitory effect of T-cell factor 3 (TCF3) on pluripotency
(Grigoryan et al., 2008; Niwa, 2011). CHIR99021 has been shown to enable the
production of iPSC from MEF cells through its’ effect on Wnt signaling which leads to
the overexpression of Oct-4 and Klf-4 (Li et al., 2009). The other school of thought is
that the Wnt-β-catenin pathway actually induces cellular differentiation. A 2012 study by
researchers at the Institute for Stem Cell and Regenerative Medicine and the Howard
Hughes Medical Institute proposed a revised interpretation of the role of Wnt-β-catenin
signaling in hESC, which supports a primary role for Wnt-β-catenin signaling in
differentiation, rather than self-renewal of hESC in culture. Davidson and colleagues
reported long-term expansion of hESC was possible with sustained inhibition of the
Wnt-β-catenin signaling pathway, indicating that Wnt-β-catenin signaling is not required
for undifferentiated hESC proliferation. Furthermore, they also found that Oct-4
functionally represses endogenous Wnt-β-catenin signaling in self-renewing hESC
(Davidson et al., 2012). Lian and colleagues came to the same conclusion when they
demonstrated that activation of the Wnt-β-catenin signaling pathway via CHIR990021
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promoted the differentiation, not self-renewal, of hESC into cardiomyocytes (Lian et al.,
2012).
More recently, the effects of PD0325091 and CHIR99021 on the induction of
endogenous pluripotency genes in reprogrammed iPSC in porcine were investigated.
Transfected porcine fetal fibroblast cells were treated with the two small molecule
inhibitors (2i), and then examined for the activation of pluripotency markers in the fetal
fibroblast cells during their conversion to iPSC by measuring alkaline-phosphatase (AP)
expression. Researchers found that there were significantly fewer AP-positive colonies
compared with cells cultured in medium supplemented only with LIF. Moreover,
endogenous expression of pluripotency-related genes, including Oct-4, Nanog, and
Sox-2, was significantly lower in 2i-treated cell cultures (Petkov et al., 2014). Other
studies have similarly reported a decrease in the expression of key pluripotency genes,
particularly Oct-4, in cells cultured with PD0325091 and CHIR99021 in porcine (Telugu
et al., 2011; Gao et al., 2013). These findings cast doubt on the effectiveness of these
small molecule inhibitors in the reprogramming of somatic cells to pluripotency in
species other than the mouse and human, opening up the possibility that PD0325091
and CHIR99021 may be ineffective on bovine cells. While further research is necessary
before any conclusions should be made, the results of these studies taken together with
the findings of this study suggest that the cow may differ from the mouse and human in
terms of pluripotent pathways.
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CHAPTER IV
EPIGENETIC EFFECTS OF TREATMENT WITH SMALL MOLECULE
INHIBITORS ON BOVINE FETAL FIBROBLAST CELLS
Introduction
The discovery of an increasing number of chemical compound that either induce
or enhance nuclear reprogramming has revealed the basic mechanisms underlying the
reprogramming process. Based on their mechanism of action, these chemical
compounds fall broadly into several classes, including those that modulate (1)
epigenetic protein activity, (2) signal transduction pathways, (3) transcription factor
activity, and (4) cell metabolism (Li et al.). CHIR99021 is among those small molecules
that modulate signal transduction pathways. CHIR99021 is a potent and selective
inhibitor or GSK3, inhibiting both GSK3β and GSK3α. GSK3 is a serine/threonine
kinase that is a key inhibitor of the Wnt signaling pathway. Because CHIR99021 inhibits
GSK3, it functions as a Wnt activator (Bain et al., 2007). The Wnt signaling pathway
plays an important role in self-renewal in both human and mouse ESC. When the
canonical Wnt signaling pathway is stimulated, β-catenin translocates to the nucleus
where it interacts with Tcf/Lef proteins to activate target genes. With regards to nuclear
reprogramming, the Wnt-β-catenin pathway is thought to help reestablish pluripotency
specifically by alleviating the inhibitory effect of T-cell factor 3 (TCF3) on pluripotency
(Grigoryan et al., 2008; Niwa, 2011). CHIR99021 has been shown to enable the
production of iPSC from MEF cells through its’ effect on Wnt signaling which leads to
the overexpression of Oct-4 and Klf-4 (Li et al., 2009). Likewise, CHIR99021 has been
found capable of substituting for c-myc (Marson et al., 2008).
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Successful nuclear reprogramming requires several highly-complex processes
and mechanisms be carried out methodically. Gene expression profiling and RNA
interference (RNAi) screening in MEF revealed three phases of nuclear reprogramming:
initiation, maturation, and stabilization (Figure 4.1). Studies showed that the first phase,
initiation, is characterized by a mesenchymal-to-epithelial transition (MET) that is driven
by BMP signaling (Samavarchi-Tehrani et al., 2010), and that the repression of the
pluripotency transgenes is required for the transition from the maturation phase to the
stabilization phase (Li et al., 2010; Golipour et al., 2012). Genome-wide analysis of
intermediate cells poised to become iPSC revealed that the reprogramming process
encompasses two distinct waves of major gene activity. The first wave occurs between
day 0 and day 3, and is characterized by the activation of genes responsible for
proliferation, metabolism, cytoskeleton organization, and the downregulation of genes
associated with development. The second wave of major gene activity occurs towards
the end of the 12 day reprogramming process, after day 9, and is characterized by the
expression of genes responsible for embryonic development and stem cell
maintenance. It is at this stage that the core pluripotency-regulating network is
activated and the pluripotent state is stabilized (Polo et al., 2012). Complimentary
studies using single-cell techniques for quantifying gene expression in cells that
undergo complete nuclear reprogramming towards pluripotency indicated that induction
of reprogramming factors provokes stochastic gene expression changes in a subset of
pluripotency genes early in the reprogramming process. These stochastic changes
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Figure 4.1. Phases of the Reprogramming Process. In the model described by
Buganim et al. (2013), the reprogramming process is divided into two phases: a long
`stochastic' phase of gene activation followed by a shorter hierarchical more
`deterministic' phase of gene activation that begins with the activation of the Sox2
locus. After induction, the four factor reprogramming cocktail, OSKM, initiates
stochastic gene expression, and fibroblasts assume one of several possible fates
(such as, apoptosis, senescence, transformation, transdifferentiation or
reprogramming). In the early phase, reprogrammable cells will increase proliferation,
undergo changes in histone modifications at somatic genes, initiate MET, and
activate DNA repair and RNA processing (Samavarchi-Tehrani et al., 2010). The
reprogrammable cells then enter an intermediate phase with an unknown ratelimiting step that delays the conversion to iPSCs and contributes to the long latency
of the process. In this phase, cells undergo a stochastic activation of pluripotency
markers, a transient activation of developmental regulators, and activation of
glycolysis (Li et al., 2010; Golipour et al., 2012). In general the transcriptional
changes in this phase are small. In some rare cases, the stochastic gene expression
will lead to the activation of "predictive markers" such as Utf1, Esrrb, Dppa2, and
Lin28, which ultimately activate Sox-2. Activation of Sox-2, either directly or
indirectly by these markers, initializes the second phase of reprogramming by
triggering a series of deterministic events that ultimately results in iPSC. In this late
phase, the cells eventually stabilize into the pluripotent state as the transgenes are
silenced, the cytoskeleton is remodeled to an ESC-like state, the epigenome is
reset, and the core pluripotency circuitry is activated (Polo et al., 2012).
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Figure 4.1. Phases of the Reprogramming
Process. In the model described by
Buganim et al. (2013), the reprogramming process is divided into two phases: a long
`stochastic' phase of gene activation followed by a shorter hierarchical more
`deterministic' phase of gene activation that begins with the activation of the Sox2

occur in tandem with MET and other events characteristic of the initiation phase, and
are essential for cells to transition to the next phase (Li et al., 2010). Unlike the
firstphase, the second phase is believed to be a more deterministic phase of gene
activation, in which the core pluripotency circuitry is activated and the pluripotent state is
stabilized in cells. Very few cells make the transition to the second phase, however, as
the majority become trapped in an intermediate phase between the first and second
phases. The low efficiency of iPSC production is thought to be due to a rate-limiting
stochastic event that is a precursor to the second phase of reprogramming (Buganim et
al., 2012).
The epigenetic changes accompanying successful nuclear reprogram include
chromatin reorganization, DNA demethylation of promoter regions of key pluripotencyassociated genes, reactivation of the somatically silenced X chromosome, and genomewide resetting of histone posttranslational modifications (Takahashi et al., 2007;
Maherali and Hochedlinger, 2009). While some of these processes, such as X
chromosome reactivation, occur late in the reprogramming process, changes in histone
modifications can be observed immediately after factor induction (Koche et al., 2011),
suggesting that alterations in histone marks are an early event that is associated with
initiation of the reprogramming process (Buganim et al., 2013). The roles of relevant
histone marks during the reprogramming process are summarized in Table 4.1. The
first of these changes to be observed is a peak of de novo deposition of H3K4me2 at
the promoter and enhancer regions of many pluripotency-associated genes, including
Sall4 and Fgf4, which are enriched for Oct-4 and Sox-2 binding sites and lack H3K4me1
or H3K4me3 marks. Concomitantly, the promoters of genes responsible for the somatic
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Table 4.1. Roles of Relevant Histone Marks during Nuclear Reprogramming
(Buganim et al., 2013)
Histone Mark

Function

Phase of
Example of
Reprogramming
Change
Table 4.1. Roles of Relevant Histone Marks
during Nuclear Reprogramming
in
which
Change
(Buganim et al., 2013)
Occurs
H3K4me2

Marks promoters
and enhancers

Early phase

Decrease at MEF
and EMT genes;
increase at
proliferation,
metabolism,
pluripotency, and
MET genes

H3K4me3

Marks active loci

Early phase

Increase at
proliferation and
metabolism genes

H3K27me3

Marks repressed
loci

Early phase

Increase at MEF
and EMT genes

H3K4me1

Marks enhancers

Early phase

Increase at
proliferation and
metabolism genes

H3K36me3

Marks
transcriptionally
active regions

Early to middle
phase

Increase at early
and late
pluripotency genes

H3K9me3

Marks
heterochromatin
regions

Late phase

Decrease at late
pluripotency genes

H3K36me2

Marks potential
regulatory regions
(such as newly
transcribed genes)

Early phase

Increase at early
pluripotency genes

H3K79me2

Marks
transcriptionally
active regions

Early to middle
phase

Decrease at MEF
and EMT genes
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cell program being to lose H3K4me2 (Koche et al., 2011). Chromatin reorganization
from the somatic state to an ESC-like one is required for the activation of the
pluripotency circuitry system. It appears that the chromatin reorganization events take
place in a coordinated and sequential manner. Rearrangement of the heterochromatin,
characterized by the presence of H3K9me3 and heterochromatin protein 1, precedes
the activation of Nanog, while enrichment of euchromatin marks occurs concurrently
with Nanog activation (Mattout et al., 2011). Taking into consideration the epigenetic
changes in histones in iPSC, H3 is the histone researched the most, as it is directly
related to genes expressed during embryonic development, such as Oct-4, Nanog, and
Sox-2. Methylation of H3K27 is associated with the suppression of various genes, and
persistent H3K27me3 blocks reprogramming. However, methylation of H3K4 is
associated with the activation of different embryonic genes. Termed “bivalent domains”,
these are regions enriched for repressive H3K27me3 and simultaneously for activating
H3K4me3 (Mikkelsen et al., 2007). Bivalent domains were initially thought to be ESCspecific, however, Mikkelsen and colleagues (2007) showed that bivalent domains are
more indicative of genes that exist in a poised state. Genes that harbor the bivalent
domain are transcriptionally silenced in ESCs, suggesting a potentially dominant role of
H3K27me3 (Maherali and Hochedlinger, 2009). In ESCs genes with bivalent domain
include a substantial number of differentiation-related genes targeted by the core
pluripotency factors. The bivalent domain on the promoters of these genes allows for a
quick response to differentiation cues. As ESC begin to differentiate, most bivalent
genes lose one of the marks, leaving either the repressive mark H3K27me3 or the
activating mark H3K4me3 (Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007). It
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should be noted that the significance of bivalent domains in key developmental genes
has recently been brought into question. Bivalent domains are not a universal feature of
pluripotent cells, nor are they unique to pluripotent cells (Mikkelsen et al., 2007). Mouse
ES cells can be maintained in a naïve state in the absence of serum by MEK and GSK3
inhibitors (2i). A recent study by Marks and colleagues showed that mouse ESC grown
in 2i medium, compared to serum-cultured mouse ESC, exhibit highly similar H3K4me3
profiles, but substantially reduced prevalence of H3K27me3, resulting in significantly
fewer bivalent domains. In spite of this, these genes are still effectively silenced (Marks
et al., 2012). Therefore, another mechanism must contribute to the repression of these
loci, and a large proportion of bivalent domains in ES cells cultured in serum are due to
acquisition of H3K27me3 at promoters (Marks et al., 2012; Liang and Zhang, 2013;
Chen and Dent, 2014).
H3K9 methylation is associated with transcription silencing and heterochromatin
formation. Genome-wide localization studies have shown that the genomic domains
marked with H3K9me3 are substantially expanded in differentiated cells compared with
ESC (Hawkins et al., 2010). H3K9 methylation has been identified as the key barrier to
the acquisition of pluripotency following nuclear reprogramming, as it has been shown
to determine cell fate between pre-iPSC and iPSC. It is thought that the switch between
euchromatin and heterochromatin is dependent upon the balance between H3K9
methylation and demethylation (Chen et al., 2013). As ESC differentiate, G9a, a H3K9specific HMT, contributes to silencing the Oct-4 locus by establishing a heterochromatin
state. Conversely, H3K9 histone demethylases (HDM) are essential to maintaining
ESC identity (Loh et al., 2007). Although H3K9 methylation has been dubbed the
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primary hindrance to fully reprogrammed iPSC, mechanistic insights into the role H3K9
methylation plays in the epigenetic reprogramming of cell fate lends H3K9 methylation
to be a tangible barrier to reprogramming, capable of being overcome. This decreasing
the levels of H3K9 methyltransferases or overexpressing H3K9 demethylases enhances
the efficiency of iPSC production (Kubicek et al., 2007; Loh et al., 2007; Shi et al.,
2008a; Shi et al., 2008b; Huang et al., 2010).
Unlike ESC which are detected only in the ICM of a blastocyst, adult stem cells
(ASC) are found in a variety of adult mammalian tissues and organs. ASC primarily
function to replenish damaged cells within these tissues and organs as a result of
normal cellular senescence or injury (Odorico et al., 2001). The differentiation potential
ASC has long been thought to be limited to cell lineages present in the organ from
which they are derived; however, several studies have challenged this notion by
demonstrating that some ASC exhibit a particularly high degree of plasticity. Unlike
terminally differentiated somatic cells, the less differentiated state of ASC can assume
the functional phenotypes and expression profiles of cells unique to other tissues
(Herzog et al., 2003). Furthermore, we and other groups have reported the presence of
Oct-4, Nanog, and Sox-2 expression in some sources of ASC in the cow, mouse, and
pig (Kues et al., 2005; Carlin et al., 2006; Coley, 2007). These findings support the
notion that ASC less differentiated than other somatic cell types, and share some
characteristics with ESC, including epigenomic regulatory program. While the
chromatin of ASC is globally less in an open configuration than that of ESC, a common
set of “stemness genes”, including regulators of chromatin, transcription, cell cycle and
survival is marked by H3K4me3, and is active in both mouse hair follicle stem cells (HF62

SC) and ESC (Lien et al., 2011). In hematopoietic stem cells (HSC), H3K4me3 is more
prevalent compared to differentiated cells types, and enhancers of differentiation genes
are marked by monomethylation of H3K4, H3K9, and H3k27, which is likely involved in
maintaining activation potential required for differentiation (Cui et al., 2009).
Once established, cellular identity is remarkably stable. Chromatin modifications
are faithfully inherited from cell division to cell division, highlighting the major hurdles
iPSC must overcome in order to be fully reprogrammed to pluripotency. The use of
small molecule compounds that target chromatin modifications and/or specific signaling
pathways have proven to be effective at overcoming these reprogramming hurdles.
Considering the significance of H3K4, H3K9, and H3K27 methylation in the
determination of cell fate, we sought to assess the effects of pre-treatment with small
molecules on these histone modifications at the promoter regions of Oct-4, Nanog, and
Sox-2.

Materials and Methods
Experimental Design
BFF cells were cultured in the presence of three small molecule inhibitors (3i):
PD0325901, a mitogen activated protein kinase/ERK kinase (MEK) inhibitor;
CHIR99021, a glycogen synthase kinase-3 (GSK3) inhibitor; and NuP0178
(NuPotential, Baton Rouge, LA), a G9a histone methyltransferase inhibitor, for a total of
14 days. On day 7 and day 14, cells were fixed using 37% formaldehyde solution, and
harvested for the preparation of chromatin using sonication shearing. The resulting
chromatin was then immunoprecipitated with antibodies directed against H3K4me3,
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H3K9me3, and H3K27me. Following immunoprecipitation, DNA was recovered and
analyzed by qRT-PCR to identify DNA loci associated with H3K4me3, H3K9me3, and
H3K27me3 on Oct-4, Nanog, and Sox-2.
Establishment of Cell Lines and Maintenance
Target cell lines were obtained from previously isolated primary cultures.
Primary cultures of fibroblast cells were established from bovine fetuses approximately
50 days old according to protocol (Giraldo et al., 2009). These Bovine Fetal Fibroblast
(BFF) cells were cultured in complete culture medium composed of Dulbecco’s Modified
Eagle Medium (DMEM) with high glucose, 10% fetal bovine serum (FBS), and 1%
penicillin/streptomycin (P/S). Once cells reached 80% confluency, cultures were
passaged by releasing cells with trypsin (0.25%). BFF cells were then resuspended in
DMEM supplemented with 10% bovine calf serum (CS) and 10% dimethyl sulfoxide
(DMSO) for cryopreservation. Cryovials containing approximately 1,000,000 BFF cells
suspended in solution were cooled at 1°C/min until reaching -80°C before storage in
liquid nitrogen.
BFF cells were thawed as needed at room temperature for 30 sec, followed by
submersion in a 38°C water bath. Cells were then washed in complete culture medium
and seeded at a density of 0.7 x 106 into 25-cm2 flasks and cultured under 5% CO2 and
90% humidity at 37°C. Because the experimental procedure required a high volume of
cells, BFF cells were expanded through repeated passaging until a sufficient number of
cells were obtained prior to each experiment.
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Treatment with Small Molecules
Chemical treatment consisted of 3 small molecule inhibitors (3i): PD0325901, a
mitogen activated protein kinase/ERK kinase (MEK) inhibitor; CHIR99021, a glycogen
synthase kinase-3 (GSK3) inhibitor; and NuP0178 (NuPotential, Baton Rouge, LA), a
G9a histone methyltransferase inhibitor. A 10mM stock solution of each inhibitor was
prepared by dissolving the crystalline solid in DMSO. 3i+ media was prepared by
diluting each stock into complete culture medium (DMEM, 10% FBS, 1% P/S) to a
concentration of 0.5µM PD0325901; 3µM CHIR99021; 1.8µM NuP0178. The
concentrations of CHIR99021 and PD0325901 utilized were consistent with previous
studies (Yu et al., 2011) and NuP0148 concentration was estimated due to its recent
development and concentration evaluation experiments carried out by NuPotential, LLC.
Once BFF cells were expanded to an adequate quantity, trypsin (0.25% EDTA)
was added to confluent cultures of BFF cells to disaggregate cells adherent to the flask,
which were then counted using a hemocytometer. Cells were then divided evenly into
treatment and control groups, approximately 2.5 x 106 cells per group. Control cells
were resuspended in complete culture medium and split evenly between three 25-cm2
flasks (approximately 0.7 x 106 per flask). Similarly, treatment cells were resuspended
in 3i+ media and split evenly between three 25-cm2 flasks (approximately 0.7 x 106 per
flask). All flasks were then placed in 37°C incubator with 5% CO2 and 90% humidity.
Media was changed every 1-2 days, and cells were passaged as needed.
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Cell Fixation and Shearing
On days 7 and 14, cells grown in a T-75 culture flask were harvested for chromatin
immunoprecipitation (ChIP) procedures using ChIP-IT® Express Magnetic Chromatin
Immunoprecipitation Kit & Sonication Shearing Kit (Active Motif, 53008). The existing
culture medium was removed from flasks, and 20 ml of freshly-prepared Fixation
Solution, composed of 37% formaldehyde and complete culture medium (540 µl 37%
formaldehyde + 20 ml complete culture medium), was added to fix protein/DNA
interactions. Cells were incubated on a shaking platform for 10 min at RT, and then
washed in ice-cold 1X PBS solution. To stop the fixation reaction, 10 ml Glycine Stop
Fix Solution (1 ml 10X Glycine Buffer+ 1 ml 10X PBS + 8 ml dH2O) was added to each
flask and incubated on a shaking platform for 5 min at RT. Cells were washed in icecold 1X PBS solution, and 5 ml of ice-cold Cell Scraping Solution (dH2O with 10% 10X
PBS) with 30 µl 100 mM PMSF was added to each flask. Adherent cells were dislodged
by thoroughly scraping the bottom of the culture flask with a rubber policeman. Cells
were collected in a 15 ml conical tube held on ice, and then pelleted by centrifugation at
720 x g for 10 min at 4°C. After discarding the supernatant, 1 µl 100 mM PMSF and 1
µl PIC were added to the pellet and placed in -80°C freezer until use in sonication step.
Due to the nature of the experimental condition, growth and survival of cell
cultures for an extended period of time proved to be quite difficult. We found that cells
did best when they were maintained in smaller culture vessels (T-25) throughout the
experiment. In this case, cells were harvested on day 7 and 14 by trypsinization, and
washed in 1 ml of Dulbecco’s Phosphate Buffered Solution (DPBS) with Ca+2 and Mg+2.
Cells were then resuspended in Fixation Solution (1 ml per 1-2 x 106 cells) and allowed
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to incubate for 10 min. In-suspension fixation was stopped by the addition of 10% 10X
Glycine. Cells were pelleted by centrifugation at 720 x g for 5 min at 4°C, and
immediately washed in ice-cold 1X PBS solution. After discarding the supernatant, 1 µl
100 mM PMSF and 1 µl PIC were added to the pellet and placed in -80°C freezer until
use in sonication step.
Optimization of Chromatin Shearing by Sonication
Chromatin shearing conditions can vary greatly depending on the cell type and
the treatment in the experiment; therefore, shearing conditions must be optimized for
these factors specific to this experiment. To do this, BFF cells were grown to 70-80%
confluency in two 15 cm plates under standard cell culture conditions (DMEM, 10%
FBS, 1% P/S; 37°C, 5% CO2). When the cells were ready to be harvested, the existing
culture medium was aspirated from the plates, and 20 ml of freshly-prepared Fixation
Solution, composed of 37% formaldehyde and complete culture medium (540 µl 37%
formaldehyde + 20 ml complete culture medium), was added to each plate to fix
protein/DNA interactions. The plates were placed on a shaking platform for 10 min at
RT, and then washed in 10 ml ice-cold 1X PBS solution. The fixation reaction was
stopped by adding 10 ml Glycine Stop-Fix Solution (1 ml 10X Glycine Buffer+ 1 ml 10X
PBS + 8 ml dH2O) to each plate. The plates were incubated on a shaking platform for 5
min at RT, and then washed in 10 ml ice-cold 1X PBS solution. Immediately before
use, 60 µl 100 mM PMSF was added to 12 ml of ice-cold Cell Scraping Solution (5.4 ml
dH2O + 600 µl 10X PBS). 5 ml of Cell Scraping Solution was added to each plate, and
cells were scraped down the plate using a rubber policeman. Cells from both plates
were collected and pooled together in a 15 ml conical tube and pelleted by
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centrifugation. After aspirating the supernatant, 1 µl 100 mM PMSF and 1 µl PIC was
added to the cell pellet and placed in a -80°C freezer overnight in order to best replicate
sample conditions. The next day, the cell pellet was thawed on ice and resuspended in
3 ml ice-cold Lysis Buffer (ChIP-IT Express Kit, Active Motif 53008) supplemented with
15 µl PMSF and 15 µl PIC. Following a 30 min incubation on ice, cells were transferred
(1 ml at a time) to a dounce homogenizer and lysed on ice with 30 strokes. The cell
lysate was collected in a 15 ml conical tube and pelleted by centrifugation. The
supernatant was discarded, and the cell pellet was resuspended in 2 ml Shearing Buffer
(ChIP-IT Express Kit, Active Motif 53008) supplemented with 10 µl PMSF and 10 µl
PIC. The cell suspension was aliquoted into equal volumes in six 1.7 ml
microcentrifuge tubes, and the tubes were placed on ice. The six aliquots of fixed
chromatin were sheared using Cole Parmer Ultrasonic Processor (Cole-Parmer, Vernon
Hills, IL, USA) (500 watts, 120 volts, 3 mm probe) at 30% amplitude using six different
conditions: (1): 20 pulses of 20 sec, 30 sec rest; (2): 30 pulses of 20 sec, 30 sec rest;
(3): 40 pulses of 20 sec, 30 sec rest; (4): 20 pulses of 30 sec, 30 sec rest; (5): 30 pulses
of 30 sec, 30 sec rest; (6): 40 pulses of 30 sec, 30 sec rest. After sonication, the tubes
were centrifuged for 10 min at 14000 x g at 4°C, and the supernatant, containing the
sheared chromatin, was collected and prepared into 50 µl aliquots. One 50 µl aliquot of
sheared chromatin from each of the six shearing conditions was subjected to cross-link
reversal and purified according to protocol described below. Samples were separated
by electrophoresis through a 1% agarose gel to determine the optimal shearing
conditions. Optimally sheared chromatin will yield a smear between 200-1500 bp.
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Based on this assay, we concluded that shearing using 25 pulses of 20 sec, 30 sec rest
yielded chromatin suitable for our experimentations.
DNA Clean Up to Assess Shearing Efficiency and DNA Concentration
To assess shearing efficiency as well as determine the DNA concentration, 150
µl of dH2O was added to 50 µl of each sheared chromatin sample, followed by 10 µl 5 M
NaCl. The tubes were then placed in a thermocycler at 65°C overnight to reverse the
cross-links. The following day, the samples were removed from the thermocycler and 1
µl RNase A (10 µg/µl) was added to each tube. The samples were then incubated for
15 min at 37°C. Next, 10 µl Proteinase K (0.5 µg/µl) was added to each sample, and
the tubes were placed in a thermocycler at 42°C to incubate for 1.5 h. After incubation,
DNA was cleaned up by adding 200 µl 1:1 phenol/chloroform TE saturated pH 8 (Sigma
Aldrich, P3803) to each sample, vortexed, and centrifuged for 5 min at 14000 x g. The
aqueous phase was then transferred to a new microcentrifuge tube, and 20 µl 3 M
Sodium Acetate pH 5.2 (Sigma-Aldrich, S2889) followed by 500 µl 100% ethanol was
added to each sample. 1 µl glycogen (20 µg/µl) (ThermoFisher Scientific, 10814010)
was also added to each sample to act as carrier for DNA in order to improve recovery.
The tubes were vortexed and placed in -20°C freezer overnight to permit DNA
precipitation. The next day, the tubes were centrifuged for 10 min at 14000 x g at 4°C
to separate the precipitate from the supernatant. After removing the supernatant, the
pellet was washed in 500 µl 70% ice cold ethanol and centrifuged again at 14000 x g for
5 min in a 4°C microcentrifuge. The supernatant was carefully removed, and the pellet
was allowed to air-dry before resuspension in 30 µl dH2O. DNA concentration was
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measured using a Thermo Scientific™ NanoDrop 2000 Spectrophotometer (Wilmington,
DE, USA).
Shearing by Sonication
Previously frozen pellets of cross-linked cells were thawed on ice, resuspended
in 1 ml of ice-cold Lysis Buffer supplemented with 5 µl PIC + 5 µl PMSF, and held on ice
for 30 min to initiate cell lysis. The cell suspension was then transferred to a glass
pestle on ice for Dounce Homigenization. Cell lysis was monitored under phase
contrast microscopy after every 10 strokes until the nuclei were sufficiently released
(between 20 and 40 strokes). The cells were then transferred to a 1.7 microcentrifuge
tubes and centrifuged at 720 x g for 10 min at 4°C. After discarding the supernatant,
the nuclei pellet was resuspended in 300 µl Shearing Buffer (ChIP-IT Express Kit,
Active Motif 53008) supplemented with 1.5 µl PIC and 1.5 µl PMSF. DNA was sheared
using Cole Parmer Ultrasonic Processor (Cole-Parmer, Vernon Hills, IL, USA) (500
watts, 120 volts, 3 mm probe) under the optimal conditions determined for the BFF cells
used in this experiment (25 pulses of 20 sec, 30 sec rest). After sonication, the sheared
chromatin was separated from the cellular debris by centrifugation at 14000 x g for 10
min at 4°C and prepared into 50 µl aliquots. One aliquot was immediately used for
assessing DNA shearing efficiency and determining the DNA concentration. The
remaining aliquots of sheared chromatin were stored at -80°C for later use.
Chromatin Immunoprecipitation
Previously frozen aliquots of sheared chromatin were thawed on ice. Once
thawed, 10 µl was removed and processed as “Input DNA”. Chromatin
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Immunoprecipitation (ChIP) reactions were set up in siliconized 1.7 ml microcentrifuge
tubes using reagents provided in ChIP-IT® Express Kit (Active Motif, 53052), with the
exception of the antibodies. Antibodies for H3K4me3 (Active Motif, 39915), H3K9me3
(Active Motif, 39765), H3K27me3 (Active Motif, 39155) were reconstituted to a
concentration of 1 µg/µl and added as the final component of the ChIP reaction. First,
the volume of sheared chromatin needed for each reaction was calculated based on the
DNA concentration that was previously determined. For reactions using less than 60 µl
of chromatin, 25 µl Protein G Magnetic Beads, 10 µl ChIP Buffer 1, 1 µl PIC, and 3 µg of
antibody were added to the appropriate volume of sheared chromatin and brought up to
a final volume of 100 µl with dH2O. For reactions requiring more than 60 µl of
chromatin, 25 µl Protein G Magnetic Beads, 20 µl ChIP Buffer 2, 2 µl PIC, and 3 µg of
antibody were added to the appropriate volume of sheared chromatin and brought up to
a final volume of 200 µl with dH2O. Chromatin was immunoprecipitated by incubating
the reactions on an end-to-end rotator overnight at 4°C. The beads were separated
from the supernatant using a magnetic stand, and quickly washed once in 800 µl ChIP
Buffer 1, followed by two washes in 800 µl ChIP Buffer 2. Chromatin was eluted by
incubating the beads in 50 µl Elution Buffer AM2 for 15 min at RT on an end-to-end
rotator. 50 µl Reverse Cross-linking Buffer was mixed with the eluted chromatin. After
the beads were separated, the supernatant was transferred to a fresh PCR tube, and
both the ChIP and Input DNA samples were incubated at 95°C for 15 min. 2 µl
Proteinase K (0.5 µg/µl) was added to each tube and successively incubated at 37°C for
1 h. Lastly, 2 µl Proteinase K Stop Solution was added to each sample.
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Chromatin Immunoprecipitation DNA Purification
Before ChIP samples can be used in PCR, the DNA must be purified away from
the components and contaminants present in an eluted ChIP sample. Chromatin IP
DNA Purification Kit (Active Motif, 58002) was used to purify DNA in all ChIP samples.
To each sample, 5 volumes DNA Purification Binding Buffer was added for every one
volume of sample. Next, 5 µl 3 M Sodium Acetate (pH 5.2) was added to determine the
solution had a pH less than 7.5. Samples were then briefly centrifuged, and the DNA
was captured by a DNA Purification Column. Column-bound DNA was washed with
750 µl Wash Buffer, and the flow through was discarded. Following another brief spin in
order to remove any residual Wash Buffer from the column, the column was transferred
to a new 1.7 microcentrifuge tube, and the DNA was eluted using 50 µl DNA Purification
Elution Buffer.
Quantitative Real-Time PCR
The methylation status of the promoter regions of Oct-4, Nanog, and Sox-2 in
both untreated and 3i+ BFF cells at day 7 and 14 was analyzed using Bio-Rad CFX
Table 4.2. Primer sets for qRT-PCR for Quantification of Target Enrichment
Gene

Primer Sequence

Oct-4

Forward TGGGTCGGGAGGGTTAGAGT
Reverse CAACAACTCACTCGCCTCCTC

Nanog

Forward AGGGATTGAAGGTTATTTGTTTT
Reverse TATCCAAACATCCAAAAATTAAAA

Sox-2

Forward GCGTTTTTTTTTTTATTTTAGTAGT
Reverse ACTTTCCCCCTTTTACAAACA
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Connect™ Real-Time PCR Detection System. The PCR primers designed to amplify
the promoter regions of these genes were previously validated by (Huang et al. (2014)).
We confirmed the specificity of these primer sequences (Table 4.2) through RT-PCR
followed by gel electrophoresis using calibrator cDNA produced from a pool of bovine
genomic DNA. Reactions were carried out in a total volume of 20 µl, which consisted of
10 µl SsoFast™ EvaGreen® Supermix (Bio Rad, 1725201), 1 µl forward and reverse
primer pairs (10 mM), 6 µl DEPC H2O, and 2 µl sample DNA. Reaction mixes were
concocted for each ChIP DNA sample, Input DNA, No Ab control sample, and a no
template negative control for all three genes. The PCR program used for the
amplification of all genes consisted of a denaturing cycle of 2 min at 94°C; 40 cycles of
PCR (94°C for 30 sec, 52ºC for 40 sec, 72ºC for 30 sec, 72ºC for 7 min).
ChIP-qPCR data must be normalized for sources of variability, including amount
of chromatin, efficiency of immunoprecipitation, and DNA recovery. Data in this study
was normalized using the Percent of Input Method. The Percent of Input Method
assumes that the ChIP qPCR signals are directly related to the amount of input
chromatin. Therefore, these values must be adjusted for using the following equation:
ΔCt [normalized ChIP] = (Ct [ChIP] - (Ct [Input] - Log2 (Input Dilution Factor), where
Input Dilution Factor= (fraction of the input chromatin saved)-1. Once the adjusted input
value was calculated for each gene in each sample, the normalized ΔCt for each ChIP
sample was calculated. Finally, the percent of input (Input %) for each sample is
calculated as follows: Input % = 100/2 (ΔCt [normalized ChIP). Data in this study is presented
as a percentage of the input, representing the enrichment of precipitated DNA
associated with either H3K4me3, H3K9me3, or H3K27me3 relative to the input sample.
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Statistical Analysis
In this experiment, a completely random design with repeated measures was
employed to assess any effect treatment with 3i+ media had on the methylation status
of H3K4, H3K9, and H3K27 at Oct-4, Nanog, and Sox-2 promoter regions over time.
The PROC MIXED with repeated measures analysis with autoregression of order one
covariance was used in SAS statistical software to determine any statistical differences
H3K4, H3K9, and H3K27 enrichment at Oct-4, Nanog, and Sox-2 promoters relative to
the input between treatment and control groups over time.

Results
The PROC MIXED with repeated measures analysis with autoregression of order
one covariance was used to determine the effect of treatment, time, and the
treatment*time interaction has on trimethylation of H3K4, H3K9, and H3K27 on the
promoters of Oct-4, Nanog, and Sox-2 in untreated BFF cells and 3i+ treated BFF cells
over time (Tables 4.2. – 4.7). For each effect, p-value ≤ 0.05 indicates a significant
difference exists. The treatment* time interaction was found to have a significant effect
on the methylation status of H3K4 in Nanog (p = 0.02), as well as H3K9 in Oct-4 (p =
0.05). Additionally, time was determined to have a significant effect on H3K27
methylation in Sox-2 (p = 0.04) (Figures 4.2 – 4.4). No significant difference in
enrichment was detected in Oct-4 H3K4, Oct-4 H3K27, Nanog H3K9, Nanog H3K27,
Sox-2 H3K4, Sox-2 H3K9 as an effect of treatment, time, or treatment*time interaction.
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Table 4.3. H3K4me3, H3K9me3, H3K27me3 Enrichment at Oct-4 promoter in
Control and Treatment BFF cells on Day 7
Sample
Oct-4 H3K4me3
Oct-4 H3K9me3
H3K27me3
Table 4.3.
H3K4me3, H3K9me3,
H3K27me3 Enrichment
at Oct-4 Oct-4
promoter
in
Control and Treatment BFF cells on Day 7
BEZ 3 P4 CON (A)
0.0059%
0.0296%
0.0449%
BEX 1 P3 CON

0.0631%

0.7239%

0.4944%

BEZ 3 P4 CON (B)

0.0110%

0.0089%

0.0126%

BEX 2 P5 CON

0.7867%

2.80%

1.30%

BEX 3 P6 CON

1.09%

0.9618%

0.0977%

BEZ 1 P2 CON

9.21%

11.19%

5.87%

BEZ 2 P4 TRMT

1.05%

1.73%

1.07%

BEX 4 P3 TRMT

0.5373%

0.6399%

0.2307%

BEZ 1 P2 TRMT
(A)

3.40%

2.19%

3.82%

BEZ 1 P2 TRMT
(B)

0.0546%

0.1797%

0.0761%
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Table 4.4. H3K4me3, H3K9me3, H3K27me3 Enrichment at Nanog promoter in
Control and Treatment BFF cells on Day 7
Sample

Nanog H3K4me3

Nanog H3K9me3

Nanog H3K27me3

Table 4.4. H3K4me3, H3K9me3, H3K27me3 Enrichment at Nanog promoter in
BEZ 3 P4and
CON
(A)
0.2860%
2.24%
Control
Treatment
BFF8.96%
cells on Day 7
BEX 1 P3 CON

0.2291%

27.55%

13.77%

BEZ 3 P4 CON (B)

177.77%

1290.63%

1041.07%

BEX 2 P5 CON

5.91%

2.13%

19.50%

BEX 3 P6 CON

1.34%

0.7494%

0.4016%

BEZ 1 P2 CON

2.92%

1.75%

5.29%

BEZ 2 P4 TRMT

8.13%

1.54%

3.15%

BEX 4 P3 TRMT

3.49%

1.00%

1.46%

BEZ 1 P2 TRMT
(A)

52.12%

59.05%

34.63%

BEZ 1 P2 TRMT
(B)

0.8373%

3.30%

8.19%
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Table 4.5. H3K4me3, H3K9me3, H3K27me3 Enrichment at Sox-2 promoter in
Control and Treatment BFF cells on Day 7
Sample

Sox-2 H3K4me3

Sox-2 H3K9me3

Sox-2 H3K27me3

BEZ 3 P4 CON (A)
331.73%%
42.93%
2.56%
Table 4.5. H3K4me3, H3K9me3, H3K27me3 Enrichment at Sox-2 promoter
in Control and Treatment BFF cells on Day 7
BEX 1 P3 CON
437.72%
1.19%
0.4216%
BEZ 3 P4 CON (B)

4.10%

35.60%

0.4809%

BEX 2 P5 CON

0.2650%

0.6480%

0.2405%

BEX 3 P6 CON

0.2438%

0.2022%

.05601%

BEZ 1 P2 CON

0.0772%

0.2920%

1.02%

BEZ 2 P4 TRMT

1.71%

0.1712%

19.34%

BEX 4 P3 TRMT

0.3826%

0.8373%

0.0880%

BEZ 1 P2 TRMT
(A)

0.8201%

4.51%

0.7922%

BEZ 1 P2 TRMT
(B)

0.1084%

1.18%

0.2438%
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Table 4.6. H3K4me3, H3K9me3, H3K27me3 Enrichment at Oct-4 promoter in
Control and Treatment BFF cells on Day 14
Sample
Oct-4 H3K4me3
Oct-4 H3K9me3
Oct-4 H3K27me3
Table 4.6. H3K4me3, H3K9me3, H3K27me3 Enrichment at Oct-4 promoter in
BEZ 2
P5 Treatment
CON
0.2022%
3.04%
Control
and
BFF0.1011%
cells on Day 14
BEZ 3 P5 CON (A)

1.18%

0.6992%

0.0022%

BEZ 1 P4 CON

0.0622%

0.4245%

0.1712%

BEZ 2 P5 TRMT

3.35%

8.30%

3.37%

BEZ 3 P5 TRMT

6.12%

22.38%

34.15%

BEX 4 P6 TRMT

5.18%

4.77%

4.77%

Table 4.7. H3K4me3, H3K9me3, H3K27me3 Enrichment at Nanog promoter in
Control and Treatment BFF cells on Day 14
Sample
Nanog H3K4me3
Nanog H3K9me3
Nanog H3K27me3
Table 4.7. H3K4me3, H3K9me3, H3K27me3 Enrichment at Nanog promoter
inBEZ
Control
BFF cells on Day 14118.92%
2 P5 and
CONTreatment175.32%
3.35%
BEZ 3 P5 CON (A)

16.27%

1.36%

7.80%

BEZ 1 P4 CON

7.38%

2.32%

11.91%

BEZ 2 P5 TRMT

3.42%

2.68%

1.80%

BEZ 3 P5 TRMT

723110.30%

184576.10%

616549.07%

BEX 4 P6 TRMT

1.96%

65.98%

93.30%
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Table 4.8. H3K4me3, H3K9me3, H3K27me3 Enrichment at Sox-2 promoter in
Control and Treatment BFF cells on Day 14
Sample

Sox-2 H3K4me3

Sox-2 H3K9me3

Sox-2 H3K27me3

Table 4.8. H3K4me3, H3K9me3, H3K27me3 Enrichment at Sox-2 promoter
2 P5and
CON
5.83%
9.54%
inBEZ
Control
Treatment BFF
cells on Day 14 3.24%
BEZ 3 P5 CON (A)

6.60%

3.82%

4.09%

BEZ 1 P4 CON

0.8032%

0.2860%

0.0930%

BEZ 2 P5 TRMT

1.16%

16.04%

69.74%

BEZ 3 P5 TRMT

1.26%

7.13%

0.3002%

BEX 4 P6 TRMT

3.37%

100.69%

27.74%
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Figure 4.2. ChIP followed by qRT-PCR was used to examine H3K4me3,
H3K9me3, and H3K27me3 enrichment at the promoter region of Oct-4 in BFF
cells treated with and without PD0325901, CHIR99021, and NuP0178 (3i) at day 7
and day 14. Enrichment is expressed as a ratio of immunoprecipitated DNA over
input DNA. Percent of Input was calculated using the following equation: Input %
= 100/2 (ΔCt [normalized ChIP), where ΔCt [normalized ChIP] = (Ct [ChIP] - (Ct [Input] Log2 (Input Dilution Factor). This data is presented in Table 4.2. and Table 4.5.
The interaction between time and treatment was observed to have a significant
effect on H3K9me3 enrichment at the Oct-4 promoter (p = 0.05), and is illustrated
above.
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Figure 4.3. ChIP followed by qRT-PCR was used to examine H3K4me3, H3K9me3,
and H3K27me3 enrichment at the promoter region of Nanog in BFF cells treated with
and without PD0325901, CHIR99021, and NuP0178 (3i) at day 7 and day 14.
Enrichment is expressed as a ratio of immunoprecipitated DNA over input DNA.
Percent of Input was calculated using the following equation: Input % = 100/2 (ΔCt
[normalized ChIP), where ΔCt [normalized ChIP] = (Ct [ChIP] - (Ct [Input] - Log2 (Input
Dilution Factor). This data is presented in Table 4.2. and Table 4.5. The interaction
between time and treatment was observed to have a significant effect on H3K4me3
enrichment at the Nanog promoter (p = 0.02), and is illustrated above.
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Figure 4.4. ChIP followed by qRT-PCR was used to examine H3K4me3, H3K9me3,
and H3K27me3 enrichment at the promoter region of Sox-2 in BFF cells treated with
and without PD0325901, CHIR99021, and NuP0178 (3i) at day 7 and day 14.
Enrichment is expressed as a ratio of immunoprecipitated DNA over input DNA.
Percent of Input was calculated using the following equation: Input % = 100/2 (ΔCt
[normalized ChIP), where ΔCt [normalized ChIP] = (Ct [ChIP] - (Ct [Input] - Log2 (Input
Dilution Factor). This data is presented in Table 4.2. and Table 4.5. Time was
observed to have a significant effect on H3K27me3 enrichment at the Sox-2
promoter (p = 0.04), and is illustrated above.

82

Discussion
The aim of this experiment was to determine what, if any, effect treatment of BFF
cells with a small molecule inhibitor cocktail comprised of CHIR99021, PD0325901, and
NuP0178 has on the methylation levels of H3K4, H3K9, and H3K27 on the promoters of
the core pluripotency-associated genes, Oct-4, Nanog, and Sox-2. Building upon this
design, we expanded our query to determine what, if any, effect the length of treatment
has on the methylation status of these histone residues. Generally methylation of H3K4
is associated with transcriptional activation, whereas methylation of H3K9 and H3K27 is
mainly associated with transcriptional repression. Several small molecules, affecting
specific signaling pathways and/or chromatin modifications, have been shown to
improve both the kinetics and efficiency of reprogramming (summarized in Table
3.1)(Zhang et al., 2012). These chemical modifiers aid in overcoming the “roadblocks”
encountered during the reprogramming process by inducing the necessary epigenetic
modifications needed to silence the somatic cell genome and completely reactivate the
ESC genome. Chemical treatment of cells prior to reprogramming can remodel the
epigenetic landscape of the somatic cell type to be more like that of ESC by removing
the repressive epigenetic marks characteristic of somatic cells and relaxing chromatin
structure to allow the reprogramming factors easier access to target genes. It has been
suggested that the genome of less differentiated cells may be more amenable to
reprogramming or require less reprogramming following the induction of pluripotency
either by SCNT or another experimental strategy (Rideout et al., 2001). Currently, the
overall efficiency of SCNT is between 0-3% (number of live offspring as a percentage of
the number of nuclear transfer embryos) (Paterson et al., 2003). While several factors
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have been identified as contributors to the inefficiency of the procedure, incomplete
epigenetic reprogramming is considered the primary reason for developmental failure of
SCNT embryos (Li et al., 2003). Based on this notion, we hypothesized that treatment
with CHIR99021, PD0325901, and NuP0178 (3i) will remodel the epigenetic landscape
of BFF cells via histone modifications so that they may ultimately be more easily
reprogrammed by means such as SCNT.
To examine the effect of 3i treatment on histone methylation at the lysine 4, 9,
and 27 residues in Oct-4, Nanog, and Sox-2, we utilized ChIP, a powerful and popular
tool for understanding the mechanisms of gene regulation by transcription factors and
modified histones. Using antibodies that recognize a specific protein or protein
modification of interest, ChIP determines the relative abundance of that protein or
protein modification of interest at one or more locations in the genome. ChIP is the
most widely used procedure for the examination of histone modification, and it has
proven to yield very valuable information on chromatin-associated processes in
numerous species. Nevertheless, the technique must be optimized by each investigator
in their model system specific. Optimization of cell harvesting, the cross-linking of
chromatin, sonication conditions, and qRT-PCR setup and analysis of ChIP-enriched
genomic DNA is very tedious, challenging, and time-consuming. Indeed, this proved to
be true for this research project. We originally used enzymatic digestion, rather than
sonication, to shear chromatin for ChIP because it is said to greatly simplify and
streamline the ChIP protocol, as well as reduce disruption of protein/DNA complexes
traditionally caused by sonication. Unfortunately, enzymatic shearing proved to be
ineffective in our model system, leading us to conclude that BFF may be among those
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cell types more resistant to cell lysis. We changed our ChIP protocol from enzymatic
shearing to mechanical shearing of chromatin by sonication. Optimization of the
amended ChIP protocol included the individual optimization of many variables including,
cell harvesting technique, cell fixation time, cell lysis by dounce homogenization,
sonication conditions, and qRT-PCR setup and analysis of the ChIP material. The ChIP
protocol optimized for our model system and implemented in this study is described in
Appendix A.
BFF cells from seven different cell lines were cultured with and without
CHIR99021, PD0325901, and NuP0178 for a total of 14 days. Using the optimized
ChIP protocol established for our model system, chromatin was prepared from these
cultures on day 7 and day 14. The resulting chromatin was then immunoprecipitated
with antibodies directed against H3K4me3, H3K9me3, and H3K27me. Following
immunoprecipitation, DNA was recovered and analyzed by qRT-PCR to identify DNA
loci associated with these histone modifications at the promoters of Oct-4, Nanog, and
Sox-2. Enrichment of precipitated DNA associated with either H3K4me3, H3K9me3, or
H3K27me3 is represented as a percentage of the input (Table 4.2 and Table 4.3). ChIP
followed by qRT-PCR revealed that a great deal of variability in H3K4, H3K9, and
H3K27 trimethylation of Oct-4, Nanog, and Sox-2 exists between samples. This is seen
in both control and treatment cells at both time points. This variability can be attributed
to several different factors, including the method used for normalizing the ChIP data.
The two most common ways to normalize data is the Fold Enrichment method
and the Percent of Input method. The Fold Enrichment method of normalization
assumes the level of background signal reproducible between different primer sets,
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samples, and replicate experiments. Fold Enrichment is calculated by taking the ChIP
signal and dividing it by the No antibody signal, representing the ChIP signal as a fold
increase relative to the background signal. Conversely, the Percent of Input method of
normalization takes the ChIP signal and divides it by the signal measured from the input
sample. The input sample is a positive control that does not go through the
immunoprecipitation process, correlating to the total available promoters in the
chromatin. It is indicative for the presence and amount of chromatin used in the ChIP
reaction. It is assumed that the obtained ChIP and No antibody signal levels are directly
related to the amount of input chromatin (Haring et al., 2007). After thoroughly
researching these two methods of normalization, we concluded that the Percent of Input
method was the best method of normalization for this experiment. Because background
signal levels do vary between primer sets, samples, and experiments, the assumption of
the Fold Enrichment method- the level of background signal is reproducible between
different primer sets- often results in a random over- or under-representation of the
ChIP data (Haring et al., 2007). While we contend that the Percent of Input method is
the optimal method of data normalization, it also has its drawbacks. The main
disadvantage of this method is caused by differences in handling the input and ChIP
samples. Because the input sample is taken so early in the preparation process, it is
subjected to many opportunities for unequal handling, possibly rendering the input and
ChIP samples different from one another. There is no consensus on how to normalize
ChIP-qPCR data within the literature because there is no perfect method of
normalization. While the Percent of Input method is the preferred method of
normalization for the majority of recent studies, the inherent nature of the procedure
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subjects data to potential variability, which could possibly be the reason for the
variability observed in this study. Lastly, it is important to remember that enrichment of
a target is not solely dependent on the quantity on the antigen associated with it.
Immunoprecipitation is affected by the accessibility of that antigen in that particular
chromatin environment, the affinity of the antibody and the precise conditions of the
immunoprecipitation process. For this reason, the level of enrichment is always
expressed as a ratio of the precipitated sequence over the input. Therefore, the
absolute levels of different antigens present in the same sequence cannot be compared
directly to one another.
Our previous examinations of Oct-4, Nanog, and Sox-2 transcript levels in
sources of ASC, including BFF, revealed capricious expression of these transcripts
between replicates (Coley, 2007). Taking this into consideration may help explain the
variability in enrichment of H3K4me3, H3K9me3, and H3K27me3 at the promoter
regions of these transcripts between samples. Furthermore, the molecular mechanisms
determining the turnover rate of histone modifications can influence data interpretation
(Clayton et al., 2006). Particular histone modifications can exist as very transient
marks, including methylation of H3K4 (Morillon et al., 2005). When a particular histone
modification has a high turnover rate, only a subset of the crosslinked nucleosomes will
carry that modification, resulting in a lower ChIP signal than when that same
modification is continuously present (Haring et al., 2007).
While the scarcity of stem cells in most tissues remains a major challenge in
studying adult stem cells, several groups were able to isolate sufficient quantities of
adult stem cells from tissues to conduct transcriptional and epigenetic profiling studies.
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Results from the limited number of studies presently available support the notion that
the chromatin states of adult stem cells are intermediate between those of pluripotent
cells and terminally differentiated cells. For example, while the chromatin of adult stem
cells is globally less `open' compared with that of ES cells, a common set of stemness
genes, including regulators of chromatin, transcription, cell cycle and survival, is marked
by H3K4me3 and is active in both HF-SCs and ES cells (Lien et al., 2011). In HSCs,
H3K4me3 is more prevalent compared with differentiated progeny, and enhancers of
differentiation genes are marked by monomethylation of H3K4, H3K9, and H3K27,
which is likely involved in the maintenance of activation potential required for
differentiation. Specifically, gene expression positively correlates with H3K4me3,
H3K4me1, H3K9me1, H3K36me3, and H4K20me1 and negatively correlates with
H3K9me3 and H3K27me3 (Cui et al., 2009; Chen and Dent, 2014).
It is important to note that Marks et al. (2012) demonstrated that mouse ESC
grown in media containing CHIR99021 and PD0325901 exhibit similar H3K4me3
profiles, but substantially reduced prevalence of H3K27me3 at promoters, many less
bivalent domains, and lower- rather than higher- expression of lineage-specific genes,
compared to those cells grown in culture-containing medium. Therefore, a large
proportion of bivalent domains in ESC cultured in serum are due to the acquisition of
H3K27me3 at promoters (Marks et al., 2012; Chen and Dent, 2014).
Transcription factors preferentially bind to `open' chromatin. Thus, epigenetic
mechanisms may set the stage for lineage-specific transcription factors by creating and
maintaining a permissive chromatin environment. Indeed, an emerging theme from
recent studies is that epigenetic pre-patterning occurs before cell fate decisions. In one
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study, Szutorisz and colleagues (2005) differentiatied mouse ES cells toward the B-cell
lineage and investigated the epigenetic regulation of gene expression. They found that
a cis-acting element in the immunoglobulin lambda-like polypeptide 1 (Igll1; also known
as λ5)–pre-B lymphocyte gene 1 (VpreB1) locus is marked by histone H3ac and
H3K4me2 at a discrete site in undifferentiated ES cells. The marked region expands
during differentiation and becomes a localized center for transcription factors and RNA
polymerase II recruitment before full activation of the Igll1 and VpreB1 genes at the preB cell stage (Szutorisz et al., 2005) Similarly, Xu et al. (2011) showed that the liver and
pancreas regulatory elements have distinct chromatin patterns in undifferentiated
endoderm cells. When the cells differentiate into hepatoblasts, acetylation of H3K9 and
H3K14 promote expression of hepatic genes, and H3K27me3 appears to repress the
expression of pancreatic genes (Xu et al., 2011). The concept of transcriptional priming
by chromatin changes is reinforced by recent studies of higher-order chromatin
structure during induced `dedifferentiation'. Circular chromosome conformation capture
with high-throughput sequencing (4C-seq) reveals that, during somatic cell
reprogramming into iPSC, the establishment of long-range interchromosomal
interactions with the Oct-4 and Nanog loci precedes transcriptional activation of these
genes (Apostolou et al., 2013; Wei et al., 2013; Chen and Dent, 2014). BFF treated
with CHIR99021, PD0325901, and NuP0178 may ultimately be more easily
reprogrammed by means such as SCNT than other somatic cells that have not
undergone pre-treatment with small molecules because they may “prime” BFF cells for
nuclear reprogramming by inducing epigenetic changes permissible to nuclear
reprogramming. While we cannot exclude that the significant effects observed in this
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experiment are simply the result of randomness, we cannot exclude that they may in
fact be due to the effects of treatment with these three small molecules priming BFF
cells for nuclear reprogramming.
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CHAPTER V
THE EFFECT OF CHIR99021 AND PD325901 TREATMENT ON
PLURIPOTENT TRANSCRIPT EXPRESSION AND HISTONE
ACETYLATION IN BOVINE FETAL FIBROBLAST CELLS
Introduction
Attempts to derive iPSC from livestock species have been met with limited
success. Although there have been reports of reprogramming somatic cells towards
pluripotency in livestock species, such as the pig, cow, and buffalo (Huang et al., 2011;
West et al., 2011; Deng et al., 2012), almost all of the reported livestock iPSC were not
capable of forming germ line chimeras. Differences in ESC and iPSC properties
between the mouse and the human have been well documented, as these have been
studied the most. Similarly, studies in other mammalian species, include the cow, pig,
and rat, for example, have shown clear differences in preimplantation development,
embryonic transcript expression patterns, and the conditions required to maintain
proliferative and undifferentiated cells in culture (Telugu et al., 2010). Even in the
mouse and human, gene expression networks that support pluripotency and
proliferation are still not completely understood, although it is clear that two or more
signal transduction pathways, probably acting in parallel must exist to account for the
different cell types. While it is likely that some version of these pathways also support
ESC identity in ungulate systems, it is thought that the cell signaling pathways
underlying pluripotency and nuclear reprogramming may differ across species;
therefore, the effectiveness of certain reprogramming techniques and enhancement
strategies may vary cross species (Telugu et al., 2010). Because the correct
expression profile of pluripotency-related genes is critical for the derivation and
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maintenance of pluripotent cells, it is necessary to identify the specific molecular
machinery regulating pluripotency in the bovine in order to create iPSC from this
species.
A number of small molecule compounds have been reported to facilitate and/or
enhance iPSC production in a variety of species. CHIR99021 and PD325901 (2i) has
been widely used to enhance to reprogramming in the mouse and human (Li et al.,
2009; Lin et al., 2009; Hanna et al., 2010; Zhou et al., 2010; Li et al., 2011; Marks et al.,
2012). For this reason, 2i has been adopted into reprogramming systems in other
species as well. However, its effectiveness in mammalian species other than the
mouse and human has been brought into question as some studies in the pig have
shown reduced pluripotent gene expression in 2i-treated cells (Telugu et al., 2011; Gao
et al., 2013; Petkov et al., 2014). It is possible that the molecular network responsible
for establishing and maintaining pluripotency in the pig may differ from that in the mouse
and human. This could similarly be the case for other mammalian species, including
bovine. Therefore, the effectiveness of 2i treatment on bovine somatic cell types needs
to be assessed to determine if it is suitable for the pre-treatment of donor cells for
SCNT. Because less-differentiated cell types are more readily reprogrammed than their
terminally differentiated counterpart, it is important to ascertain if 2i maximizes
epigenetic priming for successful reprogramming.
An important aspect of using reprogrammed cells as donor cells for SCNT is the
ability to treat and expand cells to a sufficient quantity. Typically somatic cells have a
limited proliferative capacity; therefore, it is important genetic modifications and
subsequent preparation for SCNT be accomplished before the cells enter senescence.
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It has previously been estimated that ~45 population doubling (PD) are required to
transfect, select, expand, and prepare cells for SCNT. Therefore, the longevity of donor
cells in culture is a key parameter in the development of ideal donor cells for SCNT
(Denning et al., 2001).

Materials and Methods
Experiment 1 Experimental Design
In the present study, we assessed we assessed the individual and combinatory
effects of CHIR99021 and PD0325901 treatment on Oct-4, Nanog, and Sox-2 relative
expression in BFF cells over time. BFF cells were allowed to expand in culture before
being split evenly into seven groups and treated as follows: (1) 3 µM CHIR99021
prepared from 10 mM stock solution in DMSO (Stemgent, Lexington, MA, Cat.no. 040004-02); (2) 0.5 µM PD0325901 prepared from 10 mM stock solution in DMSO
(Stemgent, Lexington, MA, Cat.no. 04-0006-02); (3) 3 µM CHIR99021 + 0.5 µM
PD0325901; (4) 1.5 µM CHIR99021 + 0.25 µM PD0325901; (5) 6 µM CHIR99021 + 1
µM PD0325901; (6) complete culture medium + 0.053% DMSO; (7) 1 µM TSA prepared
from 5 mM stock solution in DMSO (Sigma-Aldrich, T1952). BFF cells were treated for
a total of 14 days, and on days 7 and 14 mRNA was isolated from all cultures for gene
expression analysis. qRT-PCR was performed to measure transcript levels for Oct-4,
Nanog, and Sox-2 in all BFF cell cultures.
Experiment 2 Experimental Design
To explore the effects of CHIR99021 and PD0325901 treatment at varying
concentrations as mentioned above on global histone acetylation, flow cytometry was
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performed on cells harvested from the seven treatment groups on days 7 and 14 of
culture. Cells were fixed, permeabilized, and incubated with anti-acetyl-histone H3
antibody to determine the total level of H3 acetylation (H3ac) using flow cytometry.
Experiment 3 Experimental Design
As previously mentioned, we have observed adverse side effects following
treatment with 3i (CHIR99021, PD0325901, NuP0178) resulting in reduced cell survival.
To explore the potential culprit causing this, we studied growth characteristics of cells
cultured under the seven conditions mentioned above and calculated the population
doublings after 7 and 14 days of treatment.
Establishment of Cell Lines and Maintenance
Target cell lines were obtained from previously isolated primary cultures.
Primary cultures of fibroblast cells were established from bovine fetuses approximately
50 days old according to protocol (Giraldo et al., 2009). These Bovine Fetal Fibroblast
(BFF) cells were cultured in complete culture medium composed of Dulbecco’s Modified
Eagle Medium (DMEM) with high glucose, 10% fetal bovine serum (FBS), and 1%
penicillin/streptomycin (P/S). Once cells reached 80% confluency, cultures were
passaged by releasing cells with trypsin (0.25%). BFF cells were then resuspended in
DMEM supplemented with 10% bovine calf serum (CS) and 10% dimethyl sulfoxide
(DMSO) for cryopreservation. Cryovials containing approximately 1,000,000 BFF cells
suspended in solution were cooled at 1°C/min until reaching -80°C before storage in
liquid nitrogen.
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BFF cells were thawed as needed at room temperature for 30 sec, followed by
submersion in a 38°C water bath. Cells were then washed in complete culture medium
and seeded at a density of 0.3 x 106 into 6 well plates and cultured under 5% CO2 and
90% humidity at 37°C.
Treatment with Small Molecules
Once BFF cells expanded to a sufficient quantity, cells were split into 6-well
tissue culture dishes at a seeding density of 0.3 x 106 and treated under the appropriate
conditions defined for the seven treatment groups. All media was prepared with
complete culture medium (DMEM + 10% FBS + 1% P/S) and 10 mM stock solutions of
the small molecule inhibitors CHIR 99021 (Stemgent, Lexington, MA, Cat. No. 04-000402) and PD0325901 (Stemgent, Lexington, MA, Cat. No. 04-0006-02). Because the
stock solutions of the small molecule inhibitors are reconstituted in DMSO, which can
potentially be toxic to cells, DMSO was added to complete culture medium (DMEM +
10% FBS + 1% P/S + 0.053% DMSO) to control for this possibility. This concentration
of DMSO used was determined based on the concentrations of CHIR99021 and
PD0325901 in the other media preparations. Therefore, all cells were exposed to
DMSO at approximately the same concentration. The treatments are as follows: (1) 3
µM CHIR99021 (CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7) DMEM + 10%
FBS + 1% P/S + 0.053% DMSO (control). Cells were then placed placed in 37°C
incubator with 5% CO2 and 90% humidity. Media was changed every 1-2 days.
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Cell Growth Characteristics and Population Doublings
On days 7 and 14 cells were harvested for downstream applications, including
qRT-PCR and flow cytometry. Cells were tyrpsinized and washed in 1 ml of Dulbecco’s
Phosphate Buffered Solution (DPBS) with Ca+2 and Mg+2. Cells were counted using a
hemacytometer to determine concentration. The average concentration of cells from
each culture group was calculated and used to determine population doublings (PDs).
The following formula was used to calculate PDs: PD = 3.32 (log Xe – log Xb), where
Xb is the cell number at the beginning of the incubation time and Xe is the cell number
at the end of the incubation time (Patterson, 1979). Pictures of the cells in culture were
also taken on days 7 and 14 to compare growth characteristics of cells between
treatments and over time.
Isolation of mRNA
On days 7 and 14, both treatment and control cells were harvested by
trypsinization and washed in 1 ml of Dulbecco’s Phosphate Buffered Solution (DPBS)
with Ca+2 and Mg+2. Cells were counted using a hemacytometer to determine
concentration. Cells were pelleted by centrifugation and stored at -80° C to until
required for RNA purification. Because the concentration of cells harvested from
cultures was relatively low, RNA isolation was performed using RNeasy® Mini Kit
(Qiagen, Cat No. 74106). Once removed from -80°C, cell pellets were loosened by
flicking the tube, and either 350 µl (<5 x 106 ) or 600 µl (5 x 106 – 1 x 107) of Buffer RLT
was added to the tube. Cell lysates were homogenized by passing the lysate through a
21 gauge needle 5-8 times. One volume 70% ethanol was added to the lysate before

96

transferring 700 µl of the cell suspension to an RNeasy spin column placed in a
collection tube. Samples were centrifuged for 15 s at 8000 x g and flow-through
discarded. 700 µl of Buffer RW1 was added to the column and centrifuged again. Next,
the column was washed twice in 500 µl Buffer RPE. RNA was eluted by adding 30 µl
RNase-free H2O to the column followed by a 1 min spin at 8000 x g.
Quantitative Real-Time PCR
Our laboratory has previously analyzed BFF cells for Oct-4, Nanog, and Sox-2
expression, thus we have validated the specificity of primers for PAP, Oct-4, Nanog,
and Sox-2 (Coley, 2010). These primers were designed from bovine gene sequences
using the Beacon Designer 4.0 (PREMIER Biosoft International) (Table 5.1), and were
diluted to 10 mM concentration. We extended gene expression analysis to include
CTNNB1 and EGF in order to assess the specificity of CHIR99021 and PD0325901,
respectively. To explore the high incidence of cell death observed in BFF cells treated
with small molecule inhibitors, BFF cells were also analyzed for the expression of p53,
which activates the senescent pathway (Sharpless and DePinho, 2002). In addition to
PAP, β-actin and GAPDH were used as housekeeping genes for standardization. The
qRT-PCR primers used for amplification of these genes have previously been validated
by others (Table 5.1). Specificity of the primer sequences was confirmed by
amplification in calibrator sample. RNA was amplified using SsoFast™ EvaGreen
supermix (Bio- Rad Laboratories, Inc., Hercules, CA, USA). The total 20 μl real time
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Table 5.1. Primer sets for qRT-PCR for Gene Expression Analysis

Accession
Number

Primers

XM_002696890.2

Sense AGTTGGGCACTTTTGAAGACC
Antisense
AGGACCACCTCACAGTTGTTG

CTNNB1

NM_001076141.1

Forward
TGCCCATCTATGAGGGGTACG
Reverse
CGCTCCGTGAGGATCTTCATG

P53

U74486

Sense CTCAGTCCTCTGCCATACTA
Antisense
GGATCCAGGATAAGGTGAGC

β-actin

BC008633

GAPDH

U85042

Gene

EGF

Sense
CGTGACATTAAGGAGAAGCTGTGC
Antisense
CTCAGGAGGAGCAATGATCTTGAT
Sense
CCTTCATTGACCTTCACTACATGGTCTA

Antisense
TGGAAGATGGTGATGGCCTTTCCATTG
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Annealing
Temp

Reference

64°

(Takatsu et al.,
2015)

60°

(Lu et al., 2013)

50°

(Matwee et al.,
2000; Favetta et
al., 2004)

60°

(Favetta et al.,
2004)

60°

Adams, 2013

PCR mix consisted of 2 μl of cDNA, 10 µl of SsoFast™ EvaGreen Supermix, 6 μl
of nuclease-free water, and 1 μl of forward and reverse primer pairs (10 mM) for each
gene. All qRT-PCR was performed using Bio-Rad CFX Connect™ Real-Time PCR
Detection System. The PCR program used for the amplification of all primers consisted
of a denaturing cycle of 30 sec at 95°C; 40 cycles of PCR at 95°C for 5 sec and 5060°C (primer-specific annealing temperature (Table 5.1) for 20 sec; a melting curve
analysis which consisted of 95°C for 5 sec, 65°C for 1 min, followed by continuous
acquisition at 97˚C, with 5 acquistions per ˚C; and a final holding temperature of 4°C.
Data was quantified using a modified ∆∆Ct method described by (Hellemans et
al., 2007). Values are reported as relative transcription or the n-fold difference relative
to a calibrator. A mixture of cDNA from BFF cells at multiple passages was used as a
calibrator for all of the target genes. The geometric mean of PAP, GAPDH, and β-actin
was used to normalize data. Therefore, transcript abundance is calculated relative to
each reference gene and averaged using the geometric mean.
Flow Cytometry
Flow cytometry was performed using a protocol modified from (Habib et al.,
1999). On days 7 and 14, both treatment and control cells were harvested by
trypsinization and washed in 1 ml of PBST-BSA (DPBS without Ca+2 and Mg+2 + 1%
BSA + 0.1% Tween20). Cells were counted using a hemacytometer to determine
concentration of cells in each culture. The cell suspension was then divided evenly
between two Falcon® 5 mL polystyrene tubes (Cat. No. 352054) to prepare a negative
autofluorescence control for each sample. Dissociated cells were then resuspended in
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2 mL 0.25% paraformaldehyde in DPBS, and allowed to incubate for 10 min at RT for
cell fixation. Cells were centrifuged at 400 x g for 5 min and resuspended in 200 µl of
PBS containing 1% BSA (Fraction V). To detect intracellular molecules, cells were
permeabilized by slowly adding 1.8 mL of ice-cold methanol to the cell suspension.
Cells were then incubated for 30 min at -20° C. Cells were centrifuged at 400 x g for 5
min at 4°C, methanol discarded, and washed in PBS containing 1% BSA. Cells were
incubated in Anti-acetyl-Histone H3, Alexa Fluor® 488 Conjugate (Millipore, Temecula,
CA, Cat. No. 06-599-AF488) antibody diluted 1:100 in PBS containing 1% BSA for 1 h
at 4°C. Equal volume PBS containing 1% BSA was added to the negative
autofluorescence control tubes. Afterwards, cells were resuspended in 2 mL PBS
containing 1% BSA, centrifuged at 400 x g for 5 min, and the supernatant discarded.
Lastly, cells were resuspended in 300 µl 0.25% paraformaldehyde in DPBS to preserve
samples for next-day analysis.
Flow cytometric analysis was used to quantify global levels of H3ac in cells
CHIR99021 and PD0325901-indendently and at varying concentrations in combination
over time. Samples were assayed on a BD Biosciences FACS Calibur™ (Becton
Dickinson Immunocytometry Systems, San Jose, CA, USA). Labeled cells were excited
at 488 nm with a 15-mW argon laser to determine the relative level of acetylated histone
H3 measured by fluorescence of cells labeled with in Anti-acetyl-Histone H3, Alexa
Fluor® 488 Conjugate antibody. Data generated in flow cytometry was analyzed by the
BD FACStation™ data management system, and the percentage of cells manifesting
specific fluorescence for the Anti-acetyl-Histone H3, Alexa Fluor® 488 Conjugate
antibody was calculated. A negative autofluorescence control for each sample was
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used to identify forward and side scatter characteristics of the cell population, and
subsequently used to set PMT voltage and negative gates.
Statistical Analysis
In experiment 1, a completely random design with repeated measures was
employed to assess any effect treatment with CHIR99021 and PD035901independently and in varying combinations- had on target gene expression in BFF cells
over time. The PROC MIXED with repeated measures analysis with autoregression of
order one covariance was used in SAS statistical software to determine any statistical
differences in relative gene expression between treatment and control groups over time.
In experiment 2, ANOVA to determine variance in relative levels of H3ac
between control BFF cells and BFF cells treated with CHIR99021 and PD0325901indendently and at varying concentrations in combination over time.

Results
Gene Expression Analysis
The values corresponding to the relative expression of Oct-4, Nanog, Sox-2,
CTNNB1, EGF, and p53 in BFF cells treated in the seven culture systems tested on day
7 and day 14 are represented in figures 5.1, 5.2, 5.3, and 5.4. To ensure that
CHIR99021 and PD0325901 are active in bovine cells under the experimental
conditions, β-catenin (CTNNB1) and epidermal growth factor (EGF) were used as
positive control genes.
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Relative Gene Expression in CHIR99021 and PD0325901
Culture Systems at Day 7
Fold Change of Expression (Log2)
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Figure 5.1. Relative expression of Oct-4, Nanog, and Sox-2 in BFF cells
treated in the following culture systems for 7 days: (1) 3 µM CHIR99021
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7)
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental
procedures were replicated in four different BFF cell lines Target gene
abundance levels were normalized using the geometric mean of PAP,
GAPDH, and β-actin. Statistical significance determined as p = 0.05.
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Relative Gene Expression in CHIR99021 and PD0325901
Culture Systems at Day 7
Fold Change of Expression (Log2)
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Figure 5.2. Relative expression of CTNNB1, EGF, and p53 in BFF cells
treated in the following culture systems for 7 days: (1) 3 µM CHIR99021
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7)
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental
procedures were replicated in four different BFF cell lines Target gene
abundance levels were normalized using the geometric mean of PAP,
GAPDH, and β-actin. Statistical significance determined as p = 0.05 and
indicated by *.

Figure 5.2. Relative expression of CTNNB1, EGF, and p53 in BFF cells
treated in the following culture systems for 7 days: (1) 3 µM CHIR99021
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7)
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental
procedures were replicated in four different BFF cell lines Target gene
abundance levels were normalized using the geometric mean of PAP,
GAPDH, and β-actin. Statistical significance determined as p = 0.05 and
indicated by *.
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Fold Change of Expression (Log2)

Relative Gene Expression in CHIR99021 and PD0325901
Culture Systems at Day 14
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Figure 5.3. Relative expression of Oct-4, Nanog, and Sox-2 in BFF cells
treated in the following culture systems for 14 days: (1) 3 µM CHIR99021
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7)
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental
procedures were replicated in four different BFF cell lines. Target gene
abundance levels were normalized using the geometric mean of PAP,
GAPDH, and β-actin. Statistical significance determined as p = 0.05.
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Relative Gene Expression in CHIR99021 and PD0325901
Culture Systems at Day 14
Fold Change of Expression (Log2)

6

*

5
4

*

3

2
1
0
CTNNB1

EGF

p53

Gene
CHIR

PD

2i

2i*

2i**

TSA

Control

Figure 5.4. Relative expression of CTNNB1, EGF, and p53 in BFF cells
treated in the following culture systems for 14 days: (1) 3 µM CHIR99021
(CHIR); (2) 0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM
PD0325901 (2i); (4) 1.5 µM CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM
CHIR99021 + 1 µM PD0325901(2i**); (6) 1 µM Trichostatin A (TSA); (7)
DMEM + 10% FBS + 1% P/S + 0.053% DMSO (control). Experimental
procedures were replicated in four different BFF cell lines. Target gene
abundance levels were normalized using the geometric mean of PAP,
GAPDH, and β-actin. Statistical significance determined as p = 0.05 and
indicated by *.
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CHIR99021 inhibits GSK3 signaling, thus activating Wnt signaling. CTNNB1 is a major
downstream component of the Wnt signaling pathway, therefore, its expression is
interpreted as functional CHIR99021 in our system. EGF was used as a positive control
gene for specificity of PD0325901, a MEK/ERK signaling pathway inhibitor. Consistent
with the results of 3i treatment, statistical analysis comparing Oct-4, Nanog, and Sox-2
expression levels in cells treated with CHIR99021 and PD0325901- independently and
in combination at various concentrations- revealed no significance difference in gene
expression between groups at either day 7 or day 14. Conversely, a significant
difference in p53 expression was observed in 2i** media. Overall, p53 expression
increased in culture systems containing CHIR99021 and PD0325901, though not all
were of statistical significance.
The components of 2i+ culture medium involve several signaling pathways
regulating self-renewal and pluripotency. To evaluate the function of these pathways in
bovine cell types, BFF cells were treated as follows: (1) 3 µM CHIR99021 (CHIR); (2)
0.5 µM PD0325901 (PD); (3) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (4) 1.5 µM
CHIR9901 + 0.25 µM PD0325901 (2i*); (5) 6 µM CHIR99021 + 1 µM PD0325901(2i**);
(6) 1 µM Trichostatin A (TSA); (7) DMEM + 10% FBS + 1% P/S + 0.053% DMSO
(control). Pictures of cells from each treatment group on days 7 and 14 were captured
to illustrate the effects of small molecule treatment on cell growth (Figure 5.5 and 5.6).
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Figure 5.5. BFF cells cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM
PD0325901 (PD); (C) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5
µM CHIR9901 + 0.25 µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM
PD0325901(2i**); (F) DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1
µM Trichostatin A (TSA) for 7 days
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Figure 5.5. BFF cells cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM
PD0325901 (PD); (C) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5
µM CHIR9901 + 0.25 µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM
PD0325901(2i**); (F) DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1
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Figure 5.6. BFF cells cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM
PD0325901 (PD); (C) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5
µM CHIR9901 + 0.25 µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM
PD0325901(2i**); (F) DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1
µM Trichostatin A (TSA); for 14 days.
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Figure 5.6. BFF cells cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM
PD0325901 (PD); (C) 3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5
µM CHIR9901 + 0.25 µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM

Noticeable differences in cell morphology and growth can be seen between
culture groups over time. Notably, cells treated with PD, 2i, and 2i** exhibit reduced cell
growth in culture compared to the other groups. This observation correlates to the
population doublings calculated at day 7 and day 14, which show a reduction in cell
concentration (Table 5.2). All cells were seeding at a density of 0.3 x 10 6 into 6 well
plates. On days 7 and 14 cells were harvested for downstream applications, and the
cells were counted. The population doublings for DMSO treated cells were consistent
with BFF cell growth in culture (Giraldo et al., 2009). The counts at the time of harvest
for PD, 2i, 2i*, and 2i** treated cells were all either reduced or approximately the same
as the seeding density. CHIR treated populations increased to approximately ~0.5 x10 6
cells at the time of harvest, but still lower than what is anticipated for BFF cells under
normal culture conditions. This illustrates the difficulty in growing cells to a sufficient
quantity for subsequent use as donor cells for NT in the presence of these small
molecule inhibitors.
Flow Cytometric Analysis of Histone H3 Acetylation
Flow cytometric analysis was performed on cell populations treated under seven
culture conditions (CHIR; PD; 2i; 2i*; 2i**; TSA, DMSO) for 7 days and 14 days to
determine global H3ac levels (Figure 5.7 and 5.8). The experiment was performed on
four BFF cell lines, and the mean percent of positive values generated for H3ac is
reported in Table 5.3. Treatment with Trichostatin A (TSA) was used as a positive
control for our experimental designs. TSA is a member of the subgroup of HDAC
inhibitors that induce tubulin hyperacetylation. Therefore, an increased amount of H3ac
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Table 5.2. Population doubling of BFF cells after 7 and
14 days of treatment in culture media

Culture
Medium doubling
Dayof
7 BFF cells after
Day14
Table
5.2. Population
7 and
14 days of treatment in culture media
CHIR

0.83

0.56

PD

-0.60

-0.60

2i

0.40

0.20

2i*

-0.27

-0.17

2i**

-0.90

-1.26

DMSO

1.53

1.94

TSA

0.94

0.78
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Figure 5.7. Histograms representing the percentage of positive cells for
Histone H3 Acetylation in CHIR99021 and PD0325901 in BFF cells
cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM PD0325901 (PD); (C)
3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 µM CHIR9901 + 0.25
µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM PD0325901(2i**); (F)
DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1 µM Trichostatin A
(TSA) after 7 days.
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Figure 5.7. Histograms representing the percentage of positive cells for
Histone H3 Acetylation in CHIR99021 and PD0325901 in BFF cells
cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM PD0325901 (PD); (C)
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Figure 5.8. Histograms representing the percentage of positive cells for
Histone H3 Acetylation in CHIR99021 and PD0325901 in BFF cells
cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM PD0325901 (PD); (C)
3 µM CHIR99021 + 0.5 µM PD0325901 (2i); (D) 1.5 µM CHIR9901 + 0.25
µM PD0325901 (2i*); (E) 6 µM CHIR99021 + 1 µM PD0325901(2i**); (F)
DMEM + 10% FBS + 1% P/S + 0.053% DMSO; (G) 1 µM Trichostatin A
(TSA) after 14 days.
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Figure 5.8. Histograms representing the percentage of positive cells for
Histone H3 Acetylation in CHIR99021 and PD0325901 in BFF cells
cultured in (A) 3 µM CHIR99021 (CHIR); (B) 0.5 µM PD0325901 (PD); (C)

in cells cultured in TSA demonstrates that the flow cytometric techniques used in this
experiment are sufficiently specific and sensitive to detect changes in levels of
acetylated histone H3 compared to those induced by this chemical.

Table 5.3. Percentage of Positive Cells for Histone H3
Acetylation in CHIR99021 and PD0325901 Culture
Systems at Days 7 and 14
Mean %
Mean %
Culture
Positive Cells
Positive Cells
Table Medium
5.3. Percentage of Positive
Cells for Histone
D7
D14 H3
Acetylation in CHIR99021 and PD0325901 Culture
CHIR
77.0%
93.5%
Systems at Days 7 and 14
PD

80.7%

81.4%

2i

77.1%

80.4%

2i*

72.7%

78.6%

2i**

72.9%

83.3%

TSA

78.1%

91.9%

DMSO

4.0%

3.86%
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Discussion
Senescence represents an reversible state at the G1 phase of the cell cycle that
is induced by replicative exhaustion or in response to stress on the cell. Several factors
may contribute to the induction of apoptosis in cells reprogrammed towards
pluripotency, including the level of reactive oxygen species (ROS). High ROS levels
promote the modification of individual nucleotide bases, the formation of single and
double strand breaks, and leads to telomere shortening, all of which results in the
activation of p53 (Sharpless and DePinho, 2002; Favetta et al., 2004; Hong et al.,
2009). Studies in PD0325901 have shown that PD0325901 significantly inhibited the
growth of PTC cells harboring a BRAF mutation at very low concentration (10 nmol/L).
They determine the mechanism of growth inhibition to be caspase 3, indicative of
apoptosis (Henderson et al., 2010).
Recent studies suggest that p53 recognizes short and damaged telomeres,
activating the senescent pathway. Furthermore, loss of p53 function reduces the signs
of aging irrespectively of telomere length, suggesting the role for p53 rather than
telomeres in the induction of cellular senescence. In mouse and human diploid
fibroblast, downregulation of p53 expression extends their in vitro life span and leads to
rapid cell cycle re-entry. In vitro studies in mice also indicate that senescence is caused
by the activation of a p53-dependent cell cycle checkpoint that prevents cell
proliferation. The p53 tumor suppressor protein is a potent transcription factor that can
transactivate genes involved in both growth arrest and apoptosis (Helleman et al., 2011;
Henderson et al., 2010). It is important to remember that the usefulness of quiescent
cells has been attributed to their reduced transcriptional activity and chromatin
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modifications that are associated with cells in G0, which may enhance their epigenetic
plasticity (Armstrong et al., 2006).
These findings and ours are in support to those of Tsutsui et al (2011). They
concluded that he key effect of CHIR99021 therefore does not involve the induction of
Nanog. Because Nanog-overexpressing ES cells are independently blocked in
differentiation, this result further suggests that the contribution of GSK3 inhibition
extends beyond limiting differentiation. To probe this further, they evaluated whether
CHIR99021 could rescue ESC subjected to a more profound blockade of phospho-ERK.
A higher dose of PD0325901 (2 or 3 μM) almost entirely eliminates phospho-ERK and
causes growth arrest and cell death. The addition of CHIR99021 restores viability and
allows efficient expansion of undifferentiated ES cells in the near absence of ERK
signaling. Therefore, as phospho-ERK is diminished, down modulation of GSK3
becomes increasingly crucial to maintain metabolic activity, biosynthetic capacity and
overall viability. Tsutsui et al., 2011 concluded that the pivotal contribution of GSK3
inhibition is to restore full growth and viability. This may be achieved by balancing the
loss of ERK input into basic cellular processes. Additionally, they did not detect any
apoptotic activity with CHIR999021, consistent with our findings as well.
Further investigation into the actual cause of the observed cell growth inhibition
be it apoptosis or quiescence should be investigated. More sensitive techniques that
probe the actual cause of this observation, such as click-iT® TUNEL Alexa Fluor
Imaging Assay (Cat. No. C110246; Invitrogen) used by Huang et al., 2011 to detect
apoptosis in experimental cell lines. Similarly, Huang and colleagues (2011) used the
the RTCA-SP CELLigence system (Roche) to better characterize the response of
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bovine cells to comparable murine and human cells. Notably, they detected a
significant difference in proliferation, viability, morphology, and adhesion. By pinpointing
whether these cells are entering quiescence or apoptosis as a result of treatment, as
well as, species-specific response to treatment, researchers should be able to
manipulate their reprogramming mechanism to induce a stably reprogrammed cell line
for use in SCNT procedures specific for the species of interest. It should also be noted
that while the increase in p53 expression seems contradictory to the increase in H3ac, it
has been well noted that quiescent cells are easier to reprogram (Wells et al., 2013),
suggesting that this data actually work in support of one another. It is important to note
that very new studies suggest a strong genetic correlation to reprogramming ability
(Atkinson et al., 2018). This is in support of the findings of this study, suggesting that the
bovine may indeed be different than its human and murine counterpart, which may
ultimately affect its ability to reprogram to a sufficient quanta of cells suitable for
downstream applications such as SCNT. While it appears that the bovine is reliant on
the same signaling pathways as the mouse and human for nuclear reprogramming, the
mechanism of action in doing so may not be as effective as it is in their human and
murine counterparts. Alternatives to PD0325901 should be explored to see their
effectiveness in the bovine.
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CHAPTER VI
SUMMARY AND CONCLUSIONS
In 2006, Takahashi and Yamanaka reported the generation of a population of
cells similar to ESC by transfecting mouse tail fibroblast cells with four transcription
factor-encoding genes. These cells, termed induced pluripotent stem cells (iPSC), are
believed to be immensely beneficial in the study and treatment of disease as the direct
reprogramming of somatic cells provides an opportunity to generate patient- or diseasespecific pluripotent stem cells (Nakagawa et al., 2008). The supposed potential of iPSC
lies in the fact that these cells are morphologically similar to pluripotent ESC and, most
importantly, demonstrate key characteristics of pluripotent ESC, including expressing
stem cell markers, forming teratomas containing cells of all three germ layers, and
contributing to multiple cell lineages (Takahashi and Yamanaka, 2006). This landmark
discovery has opened a new frontier in the field of regenerative medicine because, for
the first time, a realistic way of generating sufficient numbers of patient-specific
pluripotent stem cells exists (Amabile and Meissner, 2009). Furthermore, this method
of generating iPSC has provided researchers with a new and unique tool to study
mammalian development and the mechanisms underlying nuclear reprogramming. The
breakthrough discovery that lineage-restricted somatic cells can be reprogrammed to a
pluripotent state through the ectopic expression of defined transcription factors
represents the culmination of over 50 years of research, and there is no sign of
research slowing down anytime soon.
Considering the many advantages of a chemical approach to nuclear
reprogramming, we first assessed the effect of pre-treatment with small molecule
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inhibitors on the expression of Oct-4, Nanog, and Sox-2 in BFF cells. The small
molecule inhibitors, CHIR99021 and PD325901, have been widely used as tools to
facilitate the generation and maintenance of iPSC (Li et al., 2009; Lin et al., 2009;
Hanna et al., 2010; Zhou et al., 2010). In these cases, CHIR99021 and PD325901 aid
in overcoming the “roadblocks” encountered during the reprogramming process by
inducing the necessary epigenetic modifications needed to silence the somatic cell
genome and completely reactivate the ESC genome. We have previously shown that
some sources of ASC, including BFF, express transcripts for the key pluripotency
genes, Oct-4, Nanog, and Sox-2 (Coley, 2007). While these cell types’ differentiating
and self-renewing capabilities are far less robust than that of ESC, we reasoned that the
same system involved in promoting the pluripotent state in mESC and hESC would
similarly work to maintain, or possibly enhance, the less differentiated state
characteristic of BFF cells. While there was no significant increase in Oct-4, Nanog, or
Sox-2 relative gene expression detected between control and treatment samples at
either day 7 or day 14, it is important to note that there was no significant decrease in
the relative expression of these transcripts over time either. Typically, pluripotent gene
expression in ASC decreases as passage number increases (Tsai and Hung, 2012), yet
the extended culture period and consequential passaging required to maintain cells in
culture for an extended period of time did not result in a significant decrease in Oct-4,
Nanog, or Sox-2 expression.
Expanding on our study and the evidence that small molecule compounds that
target chromatin modifications and/or specific signaling pathways have proven to be
effective at overcoming reprogramming hurdles, we next sought to assess the effects of
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pre-treatment with the small molecules CHIR99021, PD325901, and NuP0178 on the
methylation status of H3K4, H3K9, and H3K27 at the promoter regions of the key
pluripotency-associated genes, Oct-4, Nanog, and Sox-2. To examine the effect of 3i
treatment on histone methylation at the lysine 4, 9, and 27 residues in Oct-4, Nanog,
and Sox-2, we utilized ChIP, a powerful and popular tool for understanding the
mechanisms of gene regulation by transcription factors and modified histones. Using
antibodies that recognize a specific protein or protein modification of interest, ChIP
determines the relative abundance of that protein or protein modification of interest at
one or more locations in the genome. ChIP is the most widely used procedure for the
examination of histone modification, and it has proven to yield very valuable information
on chromatin-associated processes in numerous species. Nevertheless, the technique
must be optimized by each investigator in their model system specific. Optimization of
cell harvesting, the cross-linking of chromatin, sonication conditions, and qRT-PCR
setup and analysis of ChIP-enriched genomic DNA is very tedious, challenging, and
time-consuming. Indeed, this proved to be true for this research project. Nevertheless,
our laboratory has successfully created a working protocol for performing ChIP on BFF
cells subjected to pre-treatment with the small molecule inhibitors, CHIR99021,
PD325901, and NuP0178.
Perhaps the greatest hurdle presented in this research project, and consequently
the greatest limitation of widespread implementation of the treatment with this
combination of small molecules, is that many cells do not survive treatment.
Maintaining BFF cells treated with 3i+ media for the duration of 14 days was extremely
hard to do. Because of the extraordinarily high rate of cell death attributed to chemical
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treatment, it was extremely difficult to harvest enough cells and subsequent chromatin
required to perform ChIP. Despite countless attempts to carry out this experiment, our
laboratory was only successful at generating samples with a sufficient amount of
chromatin for ChIP a handful of times, making it difficult to statistically analyze our
results and draw any significant conclusions. While the results we obtained from this
research are interesting, there are likely better, more efficient means of chemicallyinduced nuclear reprogramming. That being said, one way to improve to overall
survival of cells following induction to reprogram towards pluripotency may be the use of
antioxidants in culture systems. Several groups have reported success following
inhibitory ROS exposure using antioxidants such as Vitamin C (Huangfu et al., 2008;
Zhong-Dong Sui et al., 2016). Furthermore, the degree of variability in the effectiveness
of treatment and the resulting outcome is, in our opinion, another great hindrance to the
widespread application of this combination of small molecule inhibitors for priming BFF
cells for nuclear reprogramming. We believed that the high variability in Oct-4, Nanog,
and Sox-2 relative gene expression, as well as H3K4me3, H3K9me3, H3K27me3 we
observed in BFF cells makes their response to pre-treatment with CHIR99021,
PD325901, and NuP0178 unpredictable in addition to being inefficient.
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APPENDIX A: PROTOCOLS
DYNABEADS® RNA ISOLATION PROTOCOL
1. Harvest cells from culture flask as per standard procedure
2. Wash cell pellet first in 1 ml of PBS with Ca+2 and Mg+2 and then in 300 µl of
lysis/binding buffer (100mM Tris HCl (pH 8.0), 500 mM LiCl, 10 mM EDTA, 1%
lithium dodecylsulfate, and 5 mM dithiothreitol)
3. Strip cells using a 21 gauge needle and a 1 ml syringe. Vortex for 10 sec.
4. Centrifuge at 12000 x g for 15 sec. and incubate at RT for 10 min.
5. Add 50 µl of the pre-washed oligo dT Dynabeads (dT25) to the tube (pre-washed
Dynabeads in lysis/binding buffer)
6. Incubate at RT for 10 min in hybridization mixer
7. Place tube in magnetic separator for 2 min
8. Remove supernatant and wash beads twice in 50 µl of Buffer A (10 mM Tris HCl
(pH 8.0), 150 mM LiCl, 1 mM EDTA, 0.1% lithium dodecylsulfate) and twice in
50 µl of Buffer B (10 mM Tris HCl (pH 8.0), 150 mM LiCl, 1 mM EDTA).
9. Elute RNA from the beads by adding 15µL of nuclease-free water and heating
the sample at 70˚C for 2 min.
10. Use sample directly for reverse transcription
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cDNA SYNTHESIS PROTOCOL
1. Mix 4 µl of iScript reaction mix, 1 µl of reverse transcriptase, and 15 µl of sample
mRNA in PCR tube (Bio-Rad Laboratories, Inc., Hercules, CA, USA)
2. Place tubes in the thermocycler and run for 5 min at 25˚C, 30 min at 42˚C,
denaturation at 85˚C for 5 min, and a final hold at 4˚C.
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qRT-PCR PROTOCOL FOR GENE EXPRESSION ANALYSIS
1. Prepare master mixes for each gene being analyzed (Oct-4, Nanog, Sox-2,
PAP). Each reaction contains 10 µl of SsoFast™ EvaGreen supermix (Bio-Rad
Laboratories, Inc., Hercules, CA, USA), 6 µl of nuclease-free water, 1 ul of each
[10 mM] primer (sense and antisense), and 2 µl of either sample or calibrator
cDNA (added later).
2. Pipette 18 µl of the appropriate master mix into the designated wells of a 96
multiwell plate tailor-made for Bio-Rad CFX Connect™ Real-Time PCR Detection
System.
3. Add 2 µl of either sample or calibrator cDNA to each designated well
4. Cover plate with sealing foil
5. Place plate in the Bio-Rad CFX Connect™ instrument and run a denaturing cycle
of 30 sec at 95°C; 45 cycles of PCR (95°C for 5 sec and 55°C for 20 sec); a
melting curve analysis which consisted of 95°C for 5 sec, 65°C for 1 min,
followed by continuous acquisition at 97˚C, with 5 acquistions per ˚C; and a final
holding temperature of 40°C.
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qRT-PCR PROTOCOL FOR ANALYSIS OF CHIP
1. Set up PCR reactions for the following templates: DNA from ChIP samples with
test antibodies (H3K4me3, H3K9me3, H3K27me3), Input DNA samples, and
DNA from ChIP performed with the negative control antibody (No Ab). Run PCR
in duplicates.
2. Prepare master mixes for each gene being analyzed for ChIP (Oct-4, Nanog, and
Sox-2). Each reaction contains 10 µl of SsoFast™ EvaGreen supermix (Bio-Rad
Laboratories, Inc., Hercules, CA, USA), 6 µl of nuclease-free water, 1 ul of each
[10 mM] primer (sense and antisense), and 2 µl of sample DNA.
3. For each PCR reaction, add 5 µl of sample DNA to 45 µl of the appropriate gene
master mix.
4. Pipette 20 µl of the sample DNA + gene mix into the designated wells of a 96
multiwell plate tailor-made for Bio-Rad CFX Connect™ Real-Time PCR Detection
System. Repeat this so that PCR is run in duplicates.
5. Cover plate with sealing foil
6. Place plate in the Bio-Rad CFX Connect™ instrument and run a denaturing cycle
of 2 min at 94°C; 40 cycles of PCR (94°C for 30 sec and 52°C for 40 sec, 72°C
for 30 sec); followed by final extension 72˚C for 7 min.
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CHROMATIN IMMUNOPRECIPITATION PROTOCOL OPTIMIZED FOR 3i-TREATED
BFF CELLS USING ChIP-IT® EXPRESS MAGNETIC CHROMATIN
IMMUNOPRECIPITATION KIT (Active Motif 53008)
Cell Fixation and Shearing

1. When cells are ready to harvest, freshly prepare the appropriate volume of
Fixation Solution and 1X PBS Solution based on number of cells
2. Harvest cells by trypsinization per standard protocol. If cells were grown in
multiple T-25 flasks, samples can be pooled at this time
3. Centrifuge 300 x g for 5 min
4. Discard supernatant and resuspend pellet in 5 mL of Fixation Solution
5. Incubate for 10 min at RT
6. Add 500 µL of 10X Glycine directly to cell suspension and mix to stop the fixation
(100 µL 10X Glycine per 1 mL of Fixation Solution)
7. Centrifuge 300 x g for 5 min
8. Wash cells in 5 mL of ice-cold 1X PBS Solution
9. Discard supernatant and add 1 µL PIC and 1 µL PMSF to cell pellet. Store at
-80°C
Shearing by Sonication
1. Thaw previously frozen cell pellet on ice and resuspend in 500 µL ice-cold Lysis
Buffer supplemented with 2.5 µL PIC and 2.5 µL PMSF. Incubate on ice for 30
min
2. Transfer cell suspension to dounce homogenizer. Dounce on ice with 40-50
strokes to aid in nuclei release. Use a phase contrast microscope to monitor cell
lysis after every 10 strokes to verify that the nuclei have been released
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3. Transfer lysate to 1.7 mL microcentrifuge tube and centrifuge 2,400 x g for 10
min at 4°C
4. Carefully discard supernatant and resuspend in 300 µL Shearing Buffer
supplemented with 1.5 µL PIC and 1.5 µL PMSF
5. Place tube in a rack holder and pack on ice, ensuring the tube is surrounded by
ice
6. Shear DNA by sonication with a Cole Palmer Ultrasonic Processor (Cole-Palmer,
Vernon Hills, IL USA) (500 watts, 120 volts, 3 mm probe) using the conditions
determined to provide optimally sheared chromatin for BFF cells in this
experiment (25 pulses of 20 sec, 30 sec rest).
7. Centrifuge 14,000 x g for 10 min at 4°C in a microcentrifuge
8. Very carefully transfer the supernatant, which contains the sheared chromatin, to
a new 1.7 mL microcentrifuge tube
9. Prepare 50 µL aliquots of sheared chromatin. One 50 µL sample will be used
immediately for assessing the efficiency of DNA shearing and determining the
DNA concentration. Store the remaining 50 µL aliquots of sheared chromatin at 80°C
DNA Cleanup to Assess Shearing Efficiency and DNA Concentration
1. Add 150 µL dH2O and 10 µL 5 M NaCl to the sheared chromatin sample
2. Incubate tubes overnight at 65°C in thermocycler to reverse the cross-links
3. Following incubation, add 1 µL RNase A to each sample and incubate at 37°C for
15 min
4. Add 10 µL Proteinase K to each sample and incubate at 42°C for 1.5 h
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5. Add 200 µL 1:1: Phenol/Chloroform TE saturated pH8 (Sigma Aldrich, P3803) to
each tube and vortex to mix thoroughly
6. Centrifuge 14,000 x g for 5 min
7. Transfer the aqueous phase to a fresh microcentrifuge tube, then add 20 µL 3 M
Sodium Acetate pH 5.2 followed by 500 µL 100% ethanol. Lastly, add 1 µL
Glycogen (20 µg/µL) to aid in recovery of a visible pellet following precipitation
8. Incubate sample at -20°C overnight
9. The next day, centrifuge sample 14,000 x g for 10 min at 4°C in microcentrifuge
10. Carefully remove and discard the supernatant, leaving the pellet undisturbed
11. Add 500 µL 70% ice cold ethanol to the tube without disturbing the pellet and
centrifuge 14,000 x g for 5 min at 4°C
12. Remove and discard supernatant, careful not to disturb the pellet. Allow pellet to
air-dry under hood
13. Once dry, resuspend the pellet in 30 µL dH20
14. Determine the DNA concentration of the sheared sample using a
spectrophotometer
15. To assess the efficiency of sonication, add 4 µL of a 6X Loading Buffer Dye to 16
µL of sheared chromatin. Load both 5 µL and 10 µL of sample on a 1% agarose
gel and run at 100V for approximately 45 min. Optimal shearing by sonication
yields a smear between 200-1500 bp.
Immunoprecipitation
1. If necessary, thaw 50 µL aliquot of chromatin on ice. Transfer 10 µL of chromatin
to a microcentrifuge tube and set aside. This is the “Input DNA”, which will be
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processed later and used as a control in PCR analysis. Store at 4° C if it will be
used within 6 h; otherwise, store at -20° C.
2. Set up the ChIP reactions by adding the components shown in the table below to
the provided siliconized 1.7 microcentrifuge tubes. Use the DNA concentration
that was determined for the sheared chromatin sample to calculate the volume of
chromatin to use. Resuspend the magnetic beads by inverting and/or vortexing
the tube before use. The antibody should be the final component added to the
reaction.
Reagent

One Reaction (if using
less than 60 µL of
chromatin)
25 µL

One Reaction (if using
more than 60 µL of
chromatin)
25 µL

10 µL

20 µL

Sheared Chromatin (725 µg)
PIC

20-60 µL

61-100 µL

1 µL

2 µL

dH2O

Antibody

Add enough so that final
volume of reaction is
100 µL
1-3 µg

Add enough so that final
volume of reaction is
200 µL
1-3 µg

Total Volume

100 µL

200 µL

Protein G Magnetic
Beads
ChIP Buffer 1

3. Cap the tube and incubate overnight at 4° C on an end-to-end rotator.
4. Following incubation, spin the tube briefly to collect liquid from inside the cap.
5. Place tube on magnetic stand to pellet the beads on side of the tube.
6. Carefully remove and discard the supernatant.
Wash Magnetic Beads
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1. Wash beads 1X with 800 µL of ChIP Buffer 1.
2. Wash beads 2X with 800 µL of ChIP Buffer 2. Allow no more than 1 min to
elapse between removing buffer and adding the next wash.
3. After the final wash, remove as much supernatant as possible without disturbing
the beads.
Elute Chromatin, Reverse Cross-links, and Treat with Proteinase K
1. Resuspend the washed beads in 50 µL Elution Buffer AM2, careful not to allow
more than 1 min to elapse between removing ChIP Buffer 2 and adding the
elution buffer.
2. Place the tube on an end-to-end rotator and incubate for 15 min at RT.
3. Briefly spin the tube to collect liquid from the cap.
4. Add 50 µL Reverse Cross-linking Buffer to the eluted chromatin and mix by
pipetting up and down. Place tube in magnetic stand, and all the beads to pellet
to the side of the tube.
5. Transfer the supernatant, which contains the chromatin, to a fresh tube.
6. Now, process the “Input DNA” by taking the 10 µL of chromatin that was set
aside earlier and thaw on ice, if necessary. Add 88 µL ChIP Buffer 2 and 2 µL
5M NaCl to the Input DNA sample, so that the final volume is 100 µL.
7. Incubate both the Input DNA and ChIP samples at 95° C for 15 min in a
thermocycler.
8. Remove the tubes from the thermocycler, allowing them to return to RT. Briefly
spin the tubes if liquid has collected in the caps. Then, add 2 µL Proteinase K to
each tube.
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9. Mix well and incubate the tubes at 37° C for 1 h. During this time, remove the
Proteinase K Stop Solution from the freezer, and allow it to sit at RT for 30 min to
1 h.
10. After incubation, allow the tubes to return to RT. Then, add 2 µL Proteinase K
Stop Solution to each tube. Briefly centrifuge the tubes to collect any liquid from
the caps. Immediately proceed with the DNA purification procedure, or store at 20° C until ready.
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CHROMATIN IP DNA PURIFICATION USING CHROMATIN IP DNA PURIFICATION
KIT (Active Motif 58002)
Purification of DNA from Chromatin IP Samples
1. If necessary, transfer ChIP samples to an Eppendorf tube, and add 5 volumes
DNA Purification Binding Buffer for every one volume of sample DNA.
2. Add 5 µL 3M Sodium Acetate to each tube and mix. Check that the color of the
DNA sample/DNA Purification Binding Buffer mixture is bright yellow, not light
orange or violet. If it is light orange or violet, adjust the pH by adding more 3M
Sodium Acetate- 5 µl at a time- until it is bright yellow in color.
3. For each sample, place a DNA purification column in the collection tube and add
each sample to its own column. Close the cap on each column, place them with
the collection tubes in a microcentrifuge, and spin 14,000 x g for 1 min at RT.
4. Remove the column from the collection tube, then remove and discard the flowthrough from the collection tube.
5. Return the column to the collection tube, and add 750 µl 80% DNA Purification
Wash Buffer (reconstituted with 100% ethanol) to the column.
6. Cap the column and centrifuge 14,000 x g for 1 min at RT.
7. Remove the column from the collection tube, then remove and discard the flowthrough from the collection tube.
8. Return the column to the collection tube. With the column caps open, centrifuge
again 14,000 x g for 2 min at RT to remove any residual DNA Purification Wash
Buffer from the column. Discard the collection tube.
9. Transfer the column to a fresh Eppendorf tube, and add 50 µl DNA Purification
Elution Buffer to the center of the column matrix. Wait for 1 min.
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10. After 1 min, centrifuge the column with the collection tube 14,000 x g for 1 min at
RT.
11. Discard the column. The DNA eluted into the Eppendorf tube is purified and
ready to be used in PCR.
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APPENDIX B: MEDIA FORMULATIONS AND STOCK SOLUTIONS
Complete Culture Medium
DMEM
10% FBS
1% P/S
3i+ Medium
DMEM
10% FBS
1% P/S
0.5 µM PD0325901
3 µM CHIR99021
1.8 µM NuP0178
Fixation Solution
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